[{"title01":"T-cell redirecting bispecific antibodies in multiple myeloma: a revolution?","title02":"T-cell redirecting bispecific antibodies in multiple myeloma: a revolution?","journal":"Blood","issue":"Blood. 2022 Apr 11:blood.2021014611. doi: 10.1182\/blood.2021014611. Online ahead of print.","author":"Moreau P, Touzeau C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35404996"},{"title01":"Agent myeloma has a new weapon from (ch1)Q","title02":"Agent myeloma has a new weapon from (ch1)Q","journal":"Blood","issue":"2022 Mar 31;139(13):1927-1928.","author":"Schmidt TM, Boise LH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35357482"},{"title01":"The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years","title02":"The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years","journal":"Leukemia","issue":"Leukemia. 2022 Apr 12. doi: 10.1038\/s41375-022-01563-8. Online ahead of print.","author":"Bazarbachi A, Boumendil A, Finel H, Khvedelidze I, Romejko-Jarosinska J, Tanase A, Akhtar S, Ben Othman T, Ma'koseh M, Afanasyev B, Cheikh J, Briones J, G\u00fclbas Z, Hamladji RM, Elverdi T, Blaise D, Mart\u00ednez C, Alma E, Halaburda K, Sousa AB, Glass B, Robinson S, Montoto S, Sureda A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35414657"},{"title01":"Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)","title02":"Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)","journal":"Leukemia","issue":"Leukemia. 2022 Apr 2. doi: 10.1038\/s41375-022-01556-7. Online ahead of print.","author":"Maschmeyer G, Bullinger L, Garcia-Vidal C, Herbrecht R, Maertens J, Menna P, Pagano L, Thiebaut-Bertrand A, Calandra T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35368047"},{"title01":"In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial","title02":"In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial","journal":"Lancet Haematol","issue":"2022 Apr;9(4):e276-e288.","author":"Marks DI, Clifton-Hadley L, Copland M, Hussain J, Menne TF, McMillan A, Moorman AV, Morley N, Okasha D, Patel B, Patrick P, Potter MN, Rowntree CJ, Kirkwood AA, Fielding AK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35358442"},{"title01":"Atypical arrhythmogenic presentation of giant cell myocarditis diagnosed after heart transplant","title02":"Atypical arrhythmogenic presentation of giant cell myocarditis diagnosed after heart transplant","journal":"Lancet","issue":"2022 Apr 9;399(10333):1411.","author":"Sekulic SP, Sekulic M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35397863"},{"title01":"Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk","title02":"Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Apr 4:JCO2102228. doi: 10.1200\/JCO.21.02228. Online ahead of print.","author":"de Tute RM, Pawlyn C, Cairns DA, Davies FE, Menzies T, Rawstron A, Jones JR, Hockaday A, Henderson R, Cook G, Drayson MT, Jenner MW, Kaiser MF, Gregory WM, Morgan GJ, Jackson GH, Owen RG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35377708"},{"title01":"Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma","title02":"Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 1. doi: 10.1111\/bjh.18166. Online ahead of print.","author":"Paszkiewicz-Kozik E, Michalski W, Taszner M, Mordak-Domaga\u0142a M, Romejko-Jarosi\u0144ska J, Knopi\u0144ska-Pos\u0142uszny W, Najda J, Borawska A, Che\u0142stowska M, \u015awierkowska M, D\u0105browska-Iwanicka A, Malenda A, Druzd-Sitek A, Konecki R, Kumiega B, Osowiecki M, Ostrowska B, Szpila T, Szyma\u0144ski M, Targo\u0144ski \u0141, Doma\u0144ska-Czy\u017c K, Pop\u0142awska L, Giebel S, Lange A, Pluta A, Zaucha JM, Rymkiewicz G, Walewski J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35362096"},{"title01":"Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival","title02":"Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 5. doi: 10.1111\/bjh.18182. Online ahead of print.","author":"D\u00e1vila J, Gonz\u00e1lez-Calle V, Escalante F, Cerd\u00e1 S, Puig N, Garc\u00eda-Sanz R, B\u00e1rez A, Montes C, L\u00f3pez R, Alonso JM, Aguilar C, Garc\u00eda-Mateo A, Labrador J, Aguilera C, Garc\u00eda-Coca A, Hern\u00e1ndez R, Mateos MV, Ocio EM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35383901"},{"title01":"How We Prevent GVHD in High Risk Patients: Post Transplant Cyclophosphamide and Beyond","title02":"How We Prevent GVHD in High Risk Patients: Post Transplant Cyclophosphamide and Beyond","journal":"Blood","issue":"Blood. 2022 Apr 11:blood.2021015129. doi: 10.1182\/blood.2021015129. Online ahead of print.","author":"Rimando JC, McCurdy SR, Luznik L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35405017"},{"title01":"Activation of the Zinc-sensing receptor GPR39 promotes T cell reconstitution after hematopoietic cell transplant in mice","title02":"Activation of the Zinc-sensing receptor GPR39 promotes T cell reconstitution after hematopoietic cell transplant in mice","journal":"Blood","issue":"Blood. 2022 Mar 25:blood.2021013950. doi: 10.1182\/blood.2021013950. Online ahead of print.","author":"Iovino L, Cooper K, deRoos P, Kinsella S, Evandy CA, Ugrai T, Mazziotta F, Ensbey KS, Granadier D, Hopwo K, Smith CW, Gagnon A, Galimberti S, Petrini M, Hill GR, Dudakov JA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35357432"},{"title01":"Towards a standard of care in transplant for WAS","title02":"Towards a standard of care in transplant for WAS","journal":"Blood","issue":"2022 Mar 31;139(13):1935-1936.","author":"Prockop SE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35357483"},{"title01":"The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years","title02":"The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years","journal":"Leukemia","issue":"Leukemia. 2022 Apr 12. doi: 10.1038\/s41375-022-01563-8. Online ahead of print.","author":"Bazarbachi A, Boumendil A, Finel H, Khvedelidze I, Romejko-Jarosinska J, Tanase A, Akhtar S, Ben Othman T, Ma'koseh M, Afanasyev B, Cheikh J, Briones J, G\u00fclbas Z, Hamladji RM, Elverdi T, Blaise D, Mart\u00ednez C, Alma E, Halaburda K, Sousa AB, Glass B, Robinson S, Montoto S, Sureda A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35414657"},{"title01":"Impact of donor vaccination on recipient response to early SARS-CoV-2 mRNA vaccination after allogeneic HSCT","title02":"Impact of donor vaccination on recipient response to early SARS-CoV-2 mRNA vaccination after allogeneic HSCT","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Apr 1:S2352-3026(22)00097-7. doi: 10.1016\/S2352-3026(22)00097-7. Online ahead of print.","author":"Leclerc M, Redjoul R, Le Bouter A, Beckerich F, Robin C, Parinet V, Pautas C, Menouche D, Bouledroua S, Roy L, Cabanne L, Nait-Sidenas Y, Harfouch E, Gautier E, Fourati S, Maury S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35378072"},{"title01":"Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk","title02":"Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Apr 4:JCO2102228. doi: 10.1200\/JCO.21.02228. Online ahead of print.","author":"de Tute RM, Pawlyn C, Cairns DA, Davies FE, Menzies T, Rawstron A, Jones JR, Hockaday A, Henderson R, Cook G, Drayson MT, Jenner MW, Kaiser MF, Gregory WM, Morgan GJ, Jackson GH, Owen RG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35377708"},{"title01":"Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival","title02":"Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 5. doi: 10.1111\/bjh.18182. Online ahead of print.","author":"D\u00e1vila J, Gonz\u00e1lez-Calle V, Escalante F, Cerd\u00e1 S, Puig N, Garc\u00eda-Sanz R, B\u00e1rez A, Montes C, L\u00f3pez R, Alonso JM, Aguilar C, Garc\u00eda-Mateo A, Labrador J, Aguilera C, Garc\u00eda-Coca A, Hern\u00e1ndez R, Mateos MV, Ocio EM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35383901"},{"title01":"Activation of the Zinc-sensing receptor GPR39 promotes T cell reconstitution after hematopoietic cell transplant in mice","title02":"Activation of the Zinc-sensing receptor GPR39 promotes T cell reconstitution after hematopoietic cell transplant in mice","journal":"Blood","issue":"Blood. 2022 Mar 25:blood.2021013950. doi: 10.1182\/blood.2021013950. Online ahead of print.","author":"Iovino L, Cooper K, deRoos P, Kinsella S, Evandy CA, Ugrai T, Mazziotta F, Ensbey KS, Granadier D, Hopwo K, Smith CW, Gagnon A, Galimberti S, Petrini M, Hill GR, Dudakov JA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35357432"},{"title01":"Sex specific definitions of anaemia reflect androgen production","title02":"Sex specific definitions of anaemia reflect androgen production","journal":"Lancet Haematol","issue":"2022 Apr;9(4):e243.","author":"Spivak JL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35358434"},{"title01":"Sex specific definitions of anaemia reflect androgen production – Authors’ reply","title02":"Sex specific definitions of anaemia reflect androgen production – Authors’ reply","journal":"Lancet Haematol","issue":"2022 Apr;9(4):e243-e244.","author":"Weyand AC, McGann P, Zholzberg M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35358435"},{"title01":"Genotype-phenotype and outcome associations in patients with Fanconi anemia: The National Cancer Institute cohort","title02":"Genotype-phenotype and outcome associations in patients with Fanconi anemia: The National Cancer Institute cohort","journal":"Haematologica","issue":"Haematologica. 2022 Apr 14. doi: 10.3324\/haematol.2021.279981. Online ahead of print.","author":"Altintas B, Giri N, McReynolds LJ, Best A, Alter BP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35417938"},{"title01":"Iron- and erythropoietin-resistant anemia in a spontaneous breast cancer mouse model","title02":"Iron- and erythropoietin-resistant anemia in a spontaneous breast cancer mouse model","journal":"Haematologica","issue":"Haematologica. 2022 Apr 7. doi: 10.3324\/haematol.2022.280732. Online ahead of print.","author":"Bregolat NF, Ruetten M, Da Silva MC, Aboouf MA, Ademi H, B\u00fcren NV, Armbruster J, Stirn M, Altamura S, Marques O, Rodriguez JMM, Samillan VJ, Singh RP, Wielockx B, Muckenthaler MU, Gassmann M, Thiersch M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35385924"},{"title01":"Functional impairment of erythropoiesis in Congenital Dyserythropoietic Anaemia type I arises at the progenitor level","title02":"Functional impairment of erythropoiesis in Congenital Dyserythropoietic Anaemia type I arises at the progenitor level","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 13. doi: 10.1111\/bjh.18167. Online ahead of print.","author":"Scott C, Bartolovic K, Clark SA, Waithe D, Hill QA, Okoli S, Renella R, Ryan K, Cahill MR, Higgs DR, Roy NBA, Buckle V, Roberts I, Babbs C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35417566"},{"title01":"Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche","title02":"Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 1. doi: 10.1111\/bjh.18163. Online ahead of print.","author":"Buesche G, Teoman H, Schneider RK, Ribezzo F, Ebert BL, Giagounidis A, G\u00f6hring G, Schlegelberger B, Bock O, Ganser A, Aul C, Germing U, Kreipe H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35362549"},{"title01":"Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia","title02":"Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia","journal":"N Engl J Med","issue":"2022 Apr 14;386(15):1421-1431.","author":"Kuter DJ, Efraim M, Mayer J, Trn\u011bn\u00fd M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35417637"},{"title01":"Erythrophagocytosis by blast cells in B-lymphoblastic leukaemia with BCR-ABL1","title02":"Erythrophagocytosis by blast cells in B-lymphoblastic leukaemia with BCR-ABL1<\/i>","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 7. doi: 10.1111\/bjh.18175. Online ahead of print.","author":"Pimentel-Villar MA, Morales-Camacho RM, Vargas MT, Jim\u00e9nez-Jambrina M, Mart\u00edn-Chac\u00f3n E, Prats-Mart\u00edn C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35389507"},{"title01":"Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukaemia","title02":"Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 12. doi: 10.1111\/bjh.18205. Online ahead of print.","author":"Shivarov V, Grigorova D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35415917"},{"title01":"Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort","title02":"Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 1. doi: 10.1111\/bjh.18147. Online ahead of print.","author":"Brivio E, Cossio A, Borra D, Silvestri D, Prunotto G, Colombini A, Verna M, Rizzari C, Biondi A, Conter V, Valsecchi MG, Balduzzi A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35362095"},{"title01":"Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy","title02":"Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 1. doi: 10.1111\/bjh.18174. Online ahead of print.","author":"Claxton DF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35362550"},{"title01":"A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial","title02":"A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 6. doi: 10.1111\/bjh.18195. Online ahead of print.","author":"Russell NH, Hills RK, Kjeldsen L, Clark RE, Ali S, Cahalin P, Thomas IF, Burnett AK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35388465"},{"title01":"Immunity in CLL: corrupt at inception?","title02":"Immunity in CLL: corrupt at inception?","journal":"Blood","issue":"2022 Apr 7;139(14):2104-2105.","author":"Danilov AV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35389445"},{"title01":"TP53 Copy Number and Protein Expression Inform Mutation Status across Risk Categories in Acute Myeloid Leukemia","title02":"TP53 Copy Number and Protein Expression Inform Mutation Status across Risk Categories in Acute Myeloid Leukemia","journal":"Blood","issue":"Blood. 2022 Apr 7:blood.2021013983. doi: 10.1182\/blood.2021013983. Online ahead of print.","author":"Tashakori M, Kadia TM, Loghavi S, Daver NG, Kanagal-Shamanna R, Pierce SR, Sui D, Wei P, Khodakarami F, Tang Z, Routbort M, Bivins C, Jabbour EJ, Medeiros LJ, Bhalla KN, Kantarjian HM, Ravandi F, Khoury JD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35390143"},{"title01":"The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years","title02":"The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years","journal":"Leukemia","issue":"Leukemia. 2022 Apr 12. doi: 10.1038\/s41375-022-01563-8. Online ahead of print.","author":"Bazarbachi A, Boumendil A, Finel H, Khvedelidze I, Romejko-Jarosinska J, Tanase A, Akhtar S, Ben Othman T, Ma'koseh M, Afanasyev B, Cheikh J, Briones J, G\u00fclbas Z, Hamladji RM, Elverdi T, Blaise D, Mart\u00ednez C, Alma E, Halaburda K, Sousa AB, Glass B, Robinson S, Montoto S, Sureda A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35414657"},{"title01":"Follicular lymphoma: life beyond the third line","title02":"Follicular lymphoma: life beyond the third line","journal":"Lancet Haematol","issue":"2022 Apr;9(4):e241-e242.","author":"Montoto S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35358433"},{"title01":"Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study","title02":"Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study","journal":"Lancet Haematol","issue":"2022 Apr;9(4):e289-e300.","author":"Casulo C, Larson MC, Lunde JJ, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan J, Flowers CR, Link BK, Maurer MJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35358443"},{"title01":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","title02":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Mar 31:S2352-3026(22)00072-2. doi: 10.1016\/S2352-3026(22)00072-2. Online ahead of print.","author":"Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Ch\u00e1vez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35366963"},{"title01":"Challenges in the development of bispecific antibodies for non-Hodgkin lymphoma","title02":"Challenges in the development of bispecific antibodies for non-Hodgkin lymphoma","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Mar 31:S2352-3026(22)00104-1. doi: 10.1016\/S2352-3026(22)00104-1. Online ahead of print.","author":"Dickinson M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35366964"},{"title01":"Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index","title02":"Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Mar 31:JCO2102063. doi: 10.1200\/JCO.21.02063. Online ahead of print.","author":"Mikhaeel NG, Heymans MW, Eertink JJ, de Vet HCW, Boellaard R, D\u00fchrsen U, Ceriani L, Schmitz C, Wiegers SE, H\u00fcttmann A, Lugtenburg PJ, Zucca E, Zwezerijnen GJC, Hoekstra OS, Zijlstra JM, Barrington SF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35357901"},{"title01":"Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?","title02":"Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Apr 4:JCO2102593. doi: 10.1200\/JCO.21.02593. Online ahead of print.","author":"Lakhotia R, Melani C, Roschewski M, Wilson WH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35377729"},{"title01":"Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia\/lymphoma","title02":"Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia\/lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Apr 14. doi: 10.3324\/haematol.2021.280352. Online ahead of print.","author":"Tanaka N, Mori S, Kiyotani K, Ota Y, Gotoh O, Kusumoto S, Nakano N, Suehiro Y, Ito A, Choi I, Ohtsuka E, Hidaka M, Nosaka K, Yoshimitsu M, Imaizumi Y, Iida S, Utsunomiya A, Noda T, Nishikawa H, Ueda R, Ishida T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35417939"},{"title01":"Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma – A study from the Danish Lymphoma Registry","title02":"Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma – A study from the Danish Lymphoma Registry","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 8. doi: 10.1111\/bjh.18180. Online ahead of print.","author":"Andersen MD, Hamilton-Dutoit S, Modvig L, Vase M, Christiansen I, Christensen JH, Dahl-S\u00f8rensen RB, Stoltenberg D, Kamper P, d'Amore F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35396711"},{"title01":"Cyclic-AMP signalling, MYC and hypoxia-inducible factor 1\u03b1 intersect to regulate angiogenesis in B-cell lymphoma","title02":"Cyclic-AMP signalling, MYC and hypoxia-inducible factor 1\u03b1 intersect to regulate angiogenesis in B-cell lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 12. doi: 10.1111\/bjh.18196. Online ahead of print.","author":"Ethiraj P, Sasi B, Holder KN, Lin AP, Qiu Z, Jaafar C, Elkhalili A, Desai P, Saksena A, Ritter JP, Aguiar RCT.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35411936"},{"title01":"Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma","title02":"Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 1. doi: 10.1111\/bjh.18166. Online ahead of print.","author":"Paszkiewicz-Kozik E, Michalski W, Taszner M, Mordak-Domaga\u0142a M, Romejko-Jarosi\u0144ska J, Knopi\u0144ska-Pos\u0142uszny W, Najda J, Borawska A, Che\u0142stowska M, \u015awierkowska M, D\u0105browska-Iwanicka A, Malenda A, Druzd-Sitek A, Konecki R, Kumiega B, Osowiecki M, Ostrowska B, Szpila T, Szyma\u0144ski M, Targo\u0144ski \u0141, Doma\u0144ska-Czy\u017c K, Pop\u0142awska L, Giebel S, Lange A, Pluta A, Zaucha JM, Rymkiewicz G, Walewski J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35362096"},{"title01":"A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial","title02":"A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 1. doi: 10.1111\/bjh.18161. Online ahead of print.","author":"Hess G, H\u00fcttmann A, Witzens-Harig M, Dreyling MH, Keller U, Marks R, Ernst T, Pott C, Viardot A, Frontzek F, Trautmann M, Ruckes C, Deuster O, Rosenwald A, Theobald M, Lenz G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35362552"},{"title01":"Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma\u00a0–\u00a0All StAGEs: A\u00a0consensus-based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute","title02":"Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma\u00a0–\u00a0All StAGEs: A\u00a0consensus-based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 1. doi: 10.1111\/bjh.18169. Online ahead of print.","author":"Shankar A, Hall GW, McKay P, Gallop-Evans E, Fielding P, Collins GP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35362554"},{"title01":"Persistent symptoms of fatigue, neuropathy and role-functioning impairment among indolent non-Hodgkin lymphoma survivors: A\u00a0longitudinal PROFILES registry study","title02":"Persistent symptoms of fatigue, neuropathy and role-functioning impairment among indolent non-Hodgkin lymphoma survivors: A\u00a0longitudinal PROFILES registry study","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 2. doi: 10.1111\/bjh.18139. Online ahead of print.","author":"Ekels A, van de Poll-Franse LV, Posthuma EFM, Kieffer J, Issa DE, Koster A, Nijziel MR, Pruijt JHFM, Stevens WBC, Tick LW, Oerlemans S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35365860"},{"title01":"Turning up the heat on salivary gland MALT lymphoma","title02":"Turning up the heat on salivary gland MALT lymphoma","journal":"Blood","issue":"2022 Apr 7;139(14):2094-2096.","author":"Quintanilla-Martinez L, Fend F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35389438"},{"title01":"Targeting IMiD-resistant T-cell lymphoma","title02":"Targeting IMiD-resistant T-cell lymphoma","journal":"Blood","issue":"2022 Mar 31;139(13):1932-1933.","author":"Liang HC, Elenitoba-Johnson KSJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35357480"},{"title01":"Melflufen in multiple myeloma: the conclusion matters – Authors’ reply","title02":"Melflufen in multiple myeloma: the conclusion matters – Authors’ reply","journal":"Lancet Haematol","issue":"2022 Apr;9(4):e244-e245.","author":"Schjesvold FH, Bakker NA, Sonneveld P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35358436"},{"title01":"Melflufen in multiple myeloma: the conclusion matters","title02":"Melflufen in multiple myeloma: the conclusion matters","journal":"Lancet Haematol","issue":"2022 Apr;9(4):e244.","author":"Hadidi SA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35358437"},{"title01":"Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile","title02":"Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Mar 31:JCO2101217. doi: 10.1200\/JCO.21.01217. Online ahead of print.","author":"Hofste Op Bruinink D, Kuiper R, van Duin M, Cupedo T, van der Velden VHJ, Hoogenboezem R, van der Holt B, Beverloo HB, Valent ET, Vermeulen M, Gay F, Broijl A, Avet-Loiseau H, Munshi NC, Musto P, Moreau P, Zweegman S, van de Donk NWCJ, Sonneveld P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35357885"},{"title01":"Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk","title02":"Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Apr 4:JCO2102228. doi: 10.1200\/JCO.21.02228. Online ahead of print.","author":"de Tute RM, Pawlyn C, Cairns DA, Davies FE, Menzies T, Rawstron A, Jones JR, Hockaday A, Henderson R, Cook G, Drayson MT, Jenner MW, Kaiser MF, Gregory WM, Morgan GJ, Jackson GH, Owen RG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35377708"},{"title01":"How I treat triple-class refractory multiple myeloma","title02":"How I treat triple-class refractory multiple myeloma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 3. doi: 10.1111\/bjh.18185. Online ahead of print.","author":"Costa LJ, Hungria V, Mohty M, Mateos MV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35373352"},{"title01":"Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database","title02":"Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 5. doi: 10.1111\/bjh.18172. Online ahead of print.","author":"LeBlanc R, Mian H, Reece D, Masih-Khan E, Kardjadj M, Jimenez-Zepeda VH, McCurdy A, Song K, Sebag M, Louzada M, White D, Stakiw J, Kotb R, Reiman A, Aslam M, Gul E, Venner CP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35383886"},{"title01":"Passenger lymphocyte syndrome following small bowel transplantation","title02":"Passenger lymphocyte syndrome following small bowel transplantation","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 11. doi: 10.1111\/bjh.18168. Online ahead of print.","author":"Obeidalla A, Staves J, Udupa V, Reddy S, Danby R, Pavord S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35405018"},{"title01":"Immunoglobulin superfamily member 8 maintains myeloid leukemia stem cells through inhibition of \u03b2-catenin degradation","title02":"Immunoglobulin superfamily member 8 maintains myeloid leukemia stem cells through inhibition of \u03b2-catenin degradation","journal":"Leukemia","issue":"Leukemia. 2022 Apr 13. doi: 10.1038\/s41375-022-01564-7. Online ahead of print.","author":"Jimbo K, Nakajima-Takagi Y, Ito T, Koide S, Nannya Y, Iwama A, Tojo A, Konuma T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35418614"},{"title01":"In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial","title02":"In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Apr;9(4):e276-e288. doi: 10.1016\/S2352-3026(22)00036-9.","author":"Marks DI, Clifton-Hadley L, Copland M, Hussain J, Menne TF, McMillan A, Moorman AV, Morley N, Okasha D, Patel B, Patrick P, Potter MN, Rowntree CJ, Kirkwood AA, Fielding AK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35358442"},{"title01":"Immunoglobulin superfamily member 8 maintains myeloid leukemia stem cells through inhibition of \u03b2-catenin degradation","title02":"Immunoglobulin superfamily member 8 maintains myeloid leukemia stem cells through inhibition of \u03b2-catenin degradation","journal":"Leukemia","issue":"Leukemia. 2022 Apr 13. doi: 10.1038\/s41375-022-01564-7. Online ahead of print.","author":"Jimbo K, Nakajima-Takagi Y, Ito T, Koide S, Nannya Y, Iwama A, Tojo A, Konuma T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35418614"},{"title01":"Single base substitution and insertion\/deletion mutational signatures in adult core binding factor acute myeloid leukemia","title02":"Single base substitution and insertion\/deletion mutational signatures in adult core binding factor acute myeloid leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Apr 1. doi: 10.1038\/s41375-022-01552-x. Online ahead of print.","author":"Gunnarsson R, Yang M, Biloglav A, Lazarevic V, Paulsson K, Johansson B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35365774"},{"title01":"Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)","title02":"Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)","journal":"Leukemia","issue":"Leukemia. 2022 Apr 2. doi: 10.1038\/s41375-022-01556-7. Online ahead of print.","author":"Maschmeyer G, Bullinger L, Garcia-Vidal C, Herbrecht R, Maertens J, Menna P, Pagano L, Thiebaut-Bertrand A, Calandra T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35368047"},{"title01":"Identification of a c-MYB-directed therapeutic for acute myeloid leukemia","title02":"Identification of a c-MYB-directed therapeutic for acute myeloid leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Apr 2. doi: 10.1038\/s41375-022-01554-9. Online ahead of print.","author":"Clesham K, Walf-Vorderw\u00fclbecke V, Gasparoli L, Virely C, Cantilena S, Tsakaneli A, Inglott S, Adams S, Samarasinghe S, Bartram J, Williams G, de Boer J, Williams O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35368048"},{"title01":"Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells","title02":"Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells","journal":"Leukemia","issue":"Leukemia. 2022 Apr 5. doi: 10.1038\/s41375-022-01553-w. Online ahead of print.","author":"Chen R, Chen Y, Xiong P, Zheleva D, Blake D, Keating MJ, Wierda WG, Plunkett W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35383271"},{"title01":"Al-Nawati tragedy: a 16-year-old patient with leukaemia and no access to cancer care","title02":"Al-Nawati tragedy: a 16-year-old patient with leukaemia and no access to cancer care","journal":"Lancet Oncol","issue":"2022 Apr;23(4):447-449.","author":"Amer F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35358449"},{"title01":"Novel strategies in the treatment of acute lymphoblastic leukaemia","title02":"Novel strategies in the treatment of acute lymphoblastic leukaemia","journal":"Lancet Haematol","issue":"2022 Apr;9(4):e240-e241.","author":"Advani AS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35358432"},{"title01":"Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial","title02":"Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial","journal":"Lancet Haematol","issue":"2022 Apr;9(4):e262-e275.","author":"Marks DI, Kirkwood AA, Rowntree CJ, Aguiar M, Bailey KE, Beaton B, Cahalin P, Castleton AZ, Clifton-Hadley L, Copland M, Goldstone AH, Kelly R, Lawrie E, Lee S, McMillan AK, McMullin MF, Menne TF, Mitchell RJ, Moorman AV, Patel B, Patrick P, Smith P, Taussig D, Yallop D, Alapi KZ, Fielding AK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35358441"},{"title01":"In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial","title02":"In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial","journal":"Lancet Haematol","issue":"2022 Apr;9(4):e276-e288.","author":"Marks DI, Clifton-Hadley L, Copland M, Hussain J, Menne TF, McMillan A, Moorman AV, Morley N, Okasha D, Patel B, Patrick P, Potter MN, Rowntree CJ, Kirkwood AA, Fielding AK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35358442"},{"title01":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations","title02":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations","journal":"Lancet Haematol","issue":"2022 Apr;9(4):e301-e311.","author":"Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, \u00c1lvarez-Larr\u00e1n A, De Stefano V, Guglielmelli P, Palandri F, Passamonti F, Barosi G, Silver RT, Hehlmann R, Kiladjian JJ, Barbui T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35358444"},{"title01":"Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile","title02":"Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Mar 31:JCO2101217. doi: 10.1200\/JCO.21.01217. Online ahead of print.","author":"Hofste Op Bruinink D, Kuiper R, van Duin M, Cupedo T, van der Velden VHJ, Hoogenboezem R, van der Holt B, Beverloo HB, Valent ET, Vermeulen M, Gay F, Broijl A, Avet-Loiseau H, Munshi NC, Musto P, Moreau P, Zweegman S, van de Donk NWCJ, Sonneveld P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35357885"},{"title01":"Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia\/lymphoma","title02":"Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia\/lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Apr 14. doi: 10.3324\/haematol.2021.280352. Online ahead of print.","author":"Tanaka N, Mori S, Kiyotani K, Ota Y, Gotoh O, Kusumoto S, Nakano N, Suehiro Y, Ito A, Choi I, Ohtsuka E, Hidaka M, Nosaka K, Yoshimitsu M, Imaizumi Y, Iida S, Utsunomiya A, Noda T, Nishikawa H, Ueda R, Ishida T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35417939"},{"title01":"The first achievement of complete remission in childhood leukemia by treatment with the folic acid antagonist aminopterin","title02":"The first achievement of complete remission in childhood leukemia by treatment with the folic acid antagonist aminopterin","journal":"Haematologica","issue":"2022 Apr 1;107(4):782.","author":"Izraeli S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35359155"},{"title01":"Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study","title02":"Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study","journal":"Haematologica","issue":"Haematologica. 2022 Apr 7. doi: 10.3324\/haematol.2021.280175. Online ahead of print.","author":"Gugliotta G, Castagnetti F, Breccia M, Levato L, Intermesoli T, D'Adda M, Salvucci M, Stagno F, Rege-Cambrin G, Tiribelli M, Martino B, Bocchia M, Cedrone M, Trabacchi E, Cavazzini F, Porretto F, Sor\u00e0 F, Simula MP, Albano F, Soverini S, Fo\u00e0 R, Pane F, Cavo M, Saglio G, Baccarani M, Rosti G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35385922"},{"title01":"T-cell large granular lymphocytic leukaemia with atypical immunophenotypes: A single-centre retrospective analysis of 17 cases","title02":"T-cell large granular lymphocytic leukaemia with atypical immunophenotypes: A single-centre retrospective analysis of 17 cases","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Apr 9. doi: 10.1111\/bjh.18184. Online ahead of print.","author":"Guo JJ, Cao L, Zhu HY, Miao Y, Du XY, Wu YJ, Wang L, Xu W, Li JY, Fan L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35396851"},{"title01":"JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia","title02":"JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Apr 11. doi: 10.1038\/s41375-022-01558-5. Online ahead of print.","author":"Bodaar K, Yamagata N, Barthe A, Landrigan J, Chonghaile TN, Burns M, Stevenson KE, Devidas M, Loh ML, Hunger SP, Wood B, Silverman LB, Teachey DT, Meijerink JP, Letai A, Gutierrez A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35411095"},{"title01":"High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia","title02":"High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Apr 13. doi: 10.1038\/s41375-022-01543-y. Online ahead of print.","author":"Ghia EM, Rassenti LZ, Choi MY, Quijada-\u00c1lamo M, Chu E, Widhopf GF 2nd, Kipps TJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35418613"},{"title01":"POD24 in follicular lymphoma: time to be “wise”","title02":"POD24 in follicular lymphoma: time to be “wise”","journal":"Blood","issue":"2022 Mar 17;139(11):1609-1610.","author":"Leonard JP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35298602"},{"title01":"Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia","title02":"Differential prognostic impact of IDH1<\/i> and IDH2<\/i> mutations in chronic myelomonocytic leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Mar 29. doi: 10.1038\/s41375-022-01551-y. Online ahead of print.","author":"Walsh C, Hunter A, Lasho T, Finke C, Ketterling R, Komrokji R, Tefferi A, Mangaonkar A, Howard M, Gangat N, Al-Kali A, Ali NA, Padron E, Patnaik MM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35351982"},{"title01":"The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT\/enhancer-binding protein alpha (CEBPAdm)","title02":"The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT\/enhancer-binding protein alpha (CEBP<\/i>Adm)","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 10. doi: 10.1111\/bjh.18113. Online ahead of print.","author":"Wei H, Zhou C, Liu B, Lin D, Li Y, Wei S, Gong B, Zhang G, Liu K, Gong X, Fang Q, Liu Y, Qiu S, Gu R, Song Z, Chen J, Yang M, Zhang J, Jin J, Wang Y, Mi Y, Wang J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35274287"},{"title01":"Toward consensus on geriatric assessment in AML","title02":"Toward consensus on geriatric assessment in AML","journal":"Blood","issue":"2022 Mar 17;139(11):1605-1606.","author":"Klepin HD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35298601"},{"title01":"Memory NK cells to forget relapsed AML","title02":"Memory NK cells to forget relapsed AML","journal":"Blood","issue":"2022 Mar 17;139(11):1607-1608.","author":"Parihar R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35298605"},{"title01":"Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia","title02":"Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia","journal":"Blood","issue":"Blood. 2022 Mar 11:blood.2021015341. doi: 10.1182\/blood.2021015341. Online ahead of print.","author":"Tracy SI, Venkatesh H, Hekim C, Heltemes Harris LM, Knutson TP, Bachanova V, Farrar MA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35275990"},{"title01":"Pseudo-Ch\u00e9diak-Higashi inclusions in BCR::ABL1-like B-lymphoblastic leukemia with IGH::EPOR rearrangement","title02":"Pseudo-Ch\u00e9diak-Higashi inclusions in BCR::ABL1<\/i>-like B-lymphoblastic leukemia with IGH::EPOR<\/i> rearrangement","journal":"Blood","issue":"2022 Mar 10;139(10):1598.","author":"Nedumannil R, Juneja S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35267003"},{"title01":"Premonoclonal B-cell lymphocytosis: the CLL cell of origin","title02":"Premonoclonal B-cell lymphocytosis: the CLL cell of origin","journal":"Blood","issue":"2022 Mar 10;139(10):1436-1437.","author":"Marti G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35267006"},{"title01":"Targeting vulnerabilities of adult T-cell leukemia","title02":"Targeting vulnerabilities of adult T-cell leukemia","journal":"Blood","issue":"2022 Mar 10;139(10):1435.","author":"Matsuoka M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35267009"},{"title01":"A BAFFling menage a trois in mantle cell lymphoma","title02":"A BAFFling menage a trois<\/i> in mantle cell lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Mar 10. doi: 10.3324\/haematol.2022.280721. Online ahead of print.","author":"Eldering E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35263987"},{"title01":"The many facets of liquid biopsies in lymphoma","title02":"The many facets of liquid biopsies in lymphoma","journal":"Blood","issue":"2022 Mar 24;139(12):1780-1781.","author":"Kurtz DM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35323879"},{"title01":"A very Burkitt-like case of Burkitt-like lymphoma with 11q aberration","title02":"A very Burkitt-like case of Burkitt-like lymphoma with 11q aberration","journal":"Blood","issue":"2022 Mar 17;139(11):1771.","author":"Aypar U, Ewalt MD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35298595"},{"title01":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","title02":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","journal":"Blood","issue":"Blood. 2022 Mar 18:blood.2021014162. doi: 10.1182\/blood.2021014162. Online ahead of print.","author":"Song Y, Zhou K, Zou DH, Zhou J, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Guo H, Zhou L, Huang J, Novotny W, Kim P, Yu Y, Wu B, Zhu J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35303070"},{"title01":"GLA\/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany","title02":"GLA\/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany","journal":"Blood","issue":"Blood. 2022 Mar 22:blood.2021015209. doi: 10.1182\/blood.2021015209. Online ahead of print.","author":"Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner-Drouet EM, Wulf GG, Marks R, Penack O, Schnetzke U, Koenecke C, von Bonin M, Stelljes M, Glass B, Baldus CD, Vucinic V, Mougiakakos D, Topp MS, Fante MA, Schroers R, Bayir LM, Borchmann P, Buecklein V, Hanoun C, Thomas S, Beelen DW, Lengerke C, Kroeger N, Dreger P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35316325"},{"title01":"Response-adapted anti-PD1 based salvage therapy for Hodgkin lymphoma with nivolumab +\/- ICE (NICE)","title02":"Response-adapted anti-PD1 based salvage therapy for Hodgkin lymphoma with nivolumab +\/- ICE (NICE)","journal":"Blood","issue":"Blood. 2022 Mar 22:blood.2022015423. doi: 10.1182\/blood.2022015423. Online ahead of print.","author":"Mei MG, Lee HJ, Palmer J, Chen RW, Tsai NC, Chen L, McBride K, Smith DL, Melgar I, Song JY, Bonjoc KC, Armenian S, Nwangwu M, Lee P, Zain J, Nikolaenko L, Popplewell L, Nademanee A, Chaudhry AA, Rosen ST, Kwak LW, Forman SJ, Herrera AF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35316328"},{"title01":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","title02":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","journal":"Leukemia","issue":"Leukemia. 2022 Mar 24. doi: 10.1038\/s41375-022-01531-2. Online ahead of print.","author":"Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, Vij R, Lindsey-Hill J, Dytfeld D, Angelucci E, Perrot A, Benjamin R, van de Donk NWCJ, Ocio EM, Scheid C, Gay F, Roeloffzen W, Rodriguez-Otero P, Broijl A, Potamianou A, Sakabedoyan C, Semerjian M, Keim S, Strulev V, Schecter JM, Vogel M, Wapenaar R, Nesheiwat T, San-Miguel J, Sonneveld P, Einsele H, Moreau P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35332278"},{"title01":"CAR T cell therapy for multiple myeloma: What have we learned?","title02":"CAR T cell therapy for multiple myeloma: What have we learned?","journal":"Leukemia","issue":"Leukemia. 2022 Mar 29. doi: 10.1038\/s41375-022-01539-8. Online ahead of print.","author":"Susanibar Adaniya S, Stadtmauer EA, Cohen AD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35351984"},{"title01":"Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma","title02":"Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Mar 25:JCO2101676. doi: 10.1200\/JCO.21.01676. Online ahead of print.","author":"Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z, Jin L, Xia J, Ma S, Liu Y, Li H, Pan B, Chen W, Fei X, Wang C, Xie X, Yu L, Wang G, Li H, Jing G, Cheng H, Zhu F, Sun H, Sang W, Li D, Li Z, Zheng J, Xu K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35333600"},{"title01":"Final analysis of the phase 3 non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma","title02":"Final analysis of the phase 3 non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma","journal":"Haematologica","issue":"Haematologica. 2022 Mar 31. doi: 10.3324\/haematol.2021.279459. Online ahead of print.","author":"Usmani SZ, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis NJ, Flogegard M, Blad\u00e9 J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Lantz K, O'Rourke L, Heuck C, Delioukina M, Qin X, Nnane I, Qi M, Mateos MV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35354247"},{"title01":"Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma","title02":"Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma","journal":"Haematologica","issue":"Haematologica. 2022 Mar 31. doi: 10.3324\/haematol.2021.280169. Online ahead of print.","author":"Harush O, Asherie N, Kfir-Erenfeld S, Adler G, Barliya T, Assayag M, Gatt ME, Stepensky P, Cohen CJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35354252"},{"title01":"Extracellular vesicles mediate the communication between multiple myeloma and bone marrow microenvironment in a NOTCH dependent way","title02":"Extracellular vesicles mediate the communication between multiple myeloma and bone marrow microenvironment in a NOTCH dependent way","journal":"Haematologica","issue":"Haematologica. 2022 Mar 10. doi: 10.3324\/haematol.2021.279716. Online ahead of print.","author":"Giannandrea D, Platonova N, Colombo M, Mazzola M, Citro V, Adami R, Maltoni F, Ancona S, Dolo V, Giusti I, Basile A, Pistocchi A, Cantone L, Bollati V, Casati L, Calzavara E, Turrini M, Lesma E, Chiaramonte R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35263984"},{"title01":"A rare presentation of a rare disease: cold haemagglutination disease as the first manifestation of IgM myeloma","title02":"A rare presentation of a rare disease: cold haemagglutination disease as the first manifestation of IgM myeloma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 21. doi: 10.1111\/bjh.18117. Online ahead of print.","author":"Khakwani M, Garnder H, Rudzki Z, Jobanputra S, Kishore B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35312064"},{"title01":"Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome","title02":"Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 11. doi: 10.1111\/bjh.18103. Online ahead of print.","author":"Baumelou M, Payssot A, Row C, Racine J, Lafon I, Bastie JN, Chevreux S, Chr\u00e9tien ML, Maynadi\u00e9 M, Caillot D, Guy J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35277859"},{"title01":"Exosomes in Multiple Myeloma: from bench to bedside","title02":"Exosomes in Multiple Myeloma: from bench to bedside","journal":"Blood","issue":"Blood. 2022 Mar 10:blood.2021014749. doi: 10.1182\/blood.2021014749. Online ahead of print.","author":"Menu E, Vanderkerken K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35271699"},{"title01":"Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia","title02":"Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia","journal":"Leukemia","issue":"Leukemia. 2022 Mar 25. doi: 10.1038\/s41375-022-01522-3. Online ahead of print.","author":"Baccarani M, Bonifazi F, Soverini S, Castagnetti F, Gugliotta G, Saber W, Estrada-Merly N, Rosti G, Gale RP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35338251"},{"title01":"Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL","title02":"Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL","journal":"Leukemia","issue":"Leukemia. 2022 Mar 28. doi: 10.1038\/s41375-022-01545-w. Online ahead of print.","author":"Kameda K, Kako S, Kim SW, Usui Y, Kato K, Fukuda T, Uchida N, Kobayashi H, Wakayama T, Sakaida E, Yano S, Imada K, Nara M, Ikeda T, Fuchida SI, Ishikawa J, Sugahara H, Kanda J, Kimura T, Ichinohe T, Atsuta Y, Kondo E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35347237"},{"title01":"Recognising inequalities in haematopoietic stem-cell transplantation and cellular therapy training","title02":"Recognising inequalities in haematopoietic stem-cell transplantation and cellular therapy training","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Mar 17:S2352-3026(22)00081-3. doi: 10.1016\/S2352-3026(22)00081-3. Online ahead of print.","author":"Horgan C, Serroukh Y, Gj\u00e6rde LK, Gagelmann N; EBMT Trainee Committee.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35313128"},{"title01":"Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO\/FIL study","title02":"Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO\/FIL study","journal":"Haematologica","issue":"Haematologica. 2022 Mar 24. doi: 10.3324\/haematol.2021.279426. Online ahead of print.","author":"Garc\u00eda-Sancho AM, Bellei M, L\u00f3pez-Parra M, Gritti G, Cort\u00e9s M, Novelli S, Panizo C, Petrucci L, Guti\u00e9rrez A, Dlouhy I, Bastos-Oreiro M, Sancho JM, Ram\u00edrez MJ, Moraleda JM, Carrillo E, Jim\u00e9nez-Ubieto AI, Jarque I, Orsucci L, Garc\u00eda-Torres E, Montalb\u00e1n C, Dodero A, Arranz R, De Las Heras N, Pascual MJ, L\u00f3pez-Jim\u00e9nez J, Spina M, Re A, De Villambrosia SG, Bobillo S, Federico M, Caballero D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35320921"},{"title01":"Mature T-cell neoplasms and stem cell transplant: the never-ending story","title02":"Mature T-cell neoplasms and stem cell transplant: the never-ending story","journal":"Haematologica","issue":"Haematologica. 2022 Mar 24. doi: 10.3324\/haematol.2022.280658. Online ahead of print.","author":"Bachy E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35320923"},{"title01":"Artificial intelligence recognition of cutaneous chronic graft-versus-host disease by a deep learning neural network","title02":"Artificial intelligence recognition of cutaneous chronic graft-versus-host disease by a deep learning neural network","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 24. doi: 10.1111\/bjh.18141. Online ahead of print.","author":"McNeil A, Parks K, Liu X, Saknite I, Chen F, Reasat T, Cronin A, Wheless L, Dawant BM, Tkaczyk ER.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35322873"},{"title01":"Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?","title02":"Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 14. doi: 10.1111\/bjh.18108. Online ahead of print.","author":"Abou-Ismail MY, Fraser R, Allbee-Johnson M, Metheny L 3rd, Ravi G, Ahn KW, Bhatt NS, Lazarus HM, de Lima M, El Jurdy N, Hematti P, Beitinjaneh AM, Nishihori T, Badawy SM, Sharma A, Pasquini MC, Savani BN, Sorror ML, Stadtmauer EA, Chhabra S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35286719"},{"title01":"Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity, an EBMT IEWP study","title02":"Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity, an EBMT IEWP study","journal":"Blood","issue":"Blood. 2022 Mar 28:blood.2022015506. doi: 10.1182\/blood.2022015506. Online ahead of print.","author":"Albert MH, Sirait T, Eikema DJ, Bakunina K, Wehr C, Suarez F, Fox ML, Mahlaoui N, Gennery AR, Lankester AC, Beier R, Bernardo ME, Bigley V, Lindemans CA, Burns SO, Carpenter B, Dybko J, G\u00fcng\u00f6r T, Hauck F, Lum SH, Balashov D, Meisel R, Moshous D, Schulz AS, Speckmann C, Slatter MA, Strahm B, Uckan-Cetinkaya D, Meyts I, Vall\u00e9e TC, Wynn R, Neven B, Morris EC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35344580"},{"title01":"HLA-DQ Heterodimers in Hematopoietic-Cell Transplantation","title02":"HLA-DQ Heterodimers in Hematopoietic-Cell Transplantation","journal":"Blood","issue":"Blood. 2022 Mar 10:blood.2022015860. doi: 10.1182\/blood.2022015860. Online ahead of print.","author":"Petersdorf EW, Bengtsson M, Horowitz MM, McKallor C, Spellman SR, Spierings E, Gooley TA, Stevenson PA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35271697"},{"title01":"Impact of diagnostic genetics on remission MRD and transplantation outcomes in older AML patients","title02":"Impact of diagnostic genetics on remission MRD and transplantation outcomes in older AML patients","journal":"Blood","issue":"Blood. 2022 Mar 14:blood.2021014520. doi: 10.1182\/blood.2021014520. Online ahead of print.","author":"Murdock HM, Kim HT, Denlinger N, Vachhani P, Hambley BC, Manning BS, Gier S, Cho C, Tsai HK, McCurdy SR, Ho VT, Koreth J, Soiffer RJ, Ritz J, Carroll MP, Vasu S, Perales MA, Wang ES, Gondek LP, Devine SM, Alyea EP, Lindsley RC, Gibson CJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35286378"},{"title01":"Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL","title02":"Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL","journal":"Leukemia","issue":"Leukemia. 2022 Mar 28. doi: 10.1038\/s41375-022-01545-w. Online ahead of print.","author":"Kameda K, Kako S, Kim SW, Usui Y, Kato K, Fukuda T, Uchida N, Kobayashi H, Wakayama T, Sakaida E, Yano S, Imada K, Nara M, Ikeda T, Fuchida SI, Ishikawa J, Sugahara H, Kanda J, Kimura T, Ichinohe T, Atsuta Y, Kondo E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35347237"},{"title01":"Recognising inequalities in haematopoietic stem-cell transplantation and cellular therapy training","title02":"Recognising inequalities in haematopoietic stem-cell transplantation and cellular therapy training","journal":"Lancet Haematol","issue":"Lancet Haematol. 2022 Mar 17:S2352-3026(22)00081-3. doi: 10.1016\/S2352-3026(22)00081-3. Online ahead of print.","author":"Horgan C, Serroukh Y, Gj\u00e6rde LK, Gagelmann N; EBMT Trainee Committee.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35313128"},{"title01":"A self-assembled leucine polymer sensitizes leukemic stem cells to chemotherapy by inhibiting autophagy in acute myeloid leukemia","title02":"A self-assembled leucine polymer sensitizes leukemic stem cells to chemotherapy by inhibiting autophagy in acute myeloid leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Mar 17. doi: 10.3324\/haematol.2021.280290. Online ahead of print.","author":"Xu X, Wang J, Tong T, Zhang W, Wang J, Ma W, Wang S, Zhou D, Wu J, Jiang L, Zhao M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35295079"},{"title01":"Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO\/FIL study","title02":"Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO\/FIL study","journal":"Haematologica","issue":"Haematologica. 2022 Mar 24. doi: 10.3324\/haematol.2021.279426. Online ahead of print.","author":"Garc\u00eda-Sancho AM, Bellei M, L\u00f3pez-Parra M, Gritti G, Cort\u00e9s M, Novelli S, Panizo C, Petrucci L, Guti\u00e9rrez A, Dlouhy I, Bastos-Oreiro M, Sancho JM, Ram\u00edrez MJ, Moraleda JM, Carrillo E, Jim\u00e9nez-Ubieto AI, Jarque I, Orsucci L, Garc\u00eda-Torres E, Montalb\u00e1n C, Dodero A, Arranz R, De Las Heras N, Pascual MJ, L\u00f3pez-Jim\u00e9nez J, Spina M, Re A, De Villambrosia SG, Bobillo S, Federico M, Caballero D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35320921"},{"title01":"Mature T-cell neoplasms and stem cell transplant: the never-ending story","title02":"Mature T-cell neoplasms and stem cell transplant: the never-ending story","journal":"Haematologica","issue":"Haematologica. 2022 Mar 24. doi: 10.3324\/haematol.2022.280658. Online ahead of print.","author":"Bachy E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35320923"},{"title01":"Immunophenotypically defined stem cell subsets in paediatric AML are highly heterogeneous and demonstrate differences in BCL-2 expression by cytogenetic subgroups","title02":"Immunophenotypically defined stem cell subsets in paediatric AML are highly heterogeneous and demonstrate differences in BCL-2 expression by cytogenetic subgroups","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 17. doi: 10.1111\/bjh.18094. Online ahead of print.","author":"Petersen MA, Rosenberg CA, Br\u00f8ndum RF, Aggerholm A, Kjeldsen E, Rahbek O, Ludvigsen M, Hasle H, Roug AS, Bill M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35298835"},{"title01":"Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?","title02":"Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 14. doi: 10.1111\/bjh.18108. Online ahead of print.","author":"Abou-Ismail MY, Fraser R, Allbee-Johnson M, Metheny L 3rd, Ravi G, Ahn KW, Bhatt NS, Lazarus HM, de Lima M, El Jurdy N, Hematti P, Beitinjaneh AM, Nishihori T, Badawy SM, Sharma A, Pasquini MC, Savani BN, Sorror ML, Stadtmauer EA, Chhabra S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35286719"},{"title01":"Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity, an EBMT IEWP study","title02":"Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity, an EBMT IEWP study","journal":"Blood","issue":"Blood. 2022 Mar 28:blood.2022015506. doi: 10.1182\/blood.2022015506. Online ahead of print.","author":"Albert MH, Sirait T, Eikema DJ, Bakunina K, Wehr C, Suarez F, Fox ML, Mahlaoui N, Gennery AR, Lankester AC, Beier R, Bernardo ME, Bigley V, Lindemans CA, Burns SO, Carpenter B, Dybko J, G\u00fcng\u00f6r T, Hauck F, Lum SH, Balashov D, Meisel R, Moshous D, Schulz AS, Speckmann C, Slatter MA, Strahm B, Uckan-Cetinkaya D, Meyts I, Vall\u00e9e TC, Wynn R, Neven B, Morris EC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35344580"},{"title01":"Angiocrine ANGPTL2 executes HSC functions in\u00a0endothelial niche","title02":"Angiocrine ANGPTL2 executes HSC functions in\u00a0endothelial niche","journal":"Blood","issue":"2022 Mar 10;139(10):1433-1434.","author":"Rafii S, Lis R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35267008"},{"title01":"HLA-DQ Heterodimers in Hematopoietic-Cell Transplantation","title02":"HLA-DQ Heterodimers in Hematopoietic-Cell Transplantation","journal":"Blood","issue":"Blood. 2022 Mar 10:blood.2022015860. doi: 10.1182\/blood.2022015860. Online ahead of print.","author":"Petersdorf EW, Bengtsson M, Horowitz MM, McKallor C, Spellman SR, Spierings E, Gooley TA, Stevenson PA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35271697"},{"title01":"BRAFV600E-positive cells as molecular markers of bone marrow disease in pediatric Langerhans cell histiocytosis","title02":"BRAF<\/i>V600E<\/sup>-positive cells as molecular markers of bone marrow disease in pediatric Langerhans cell histiocytosis","journal":"Haematologica","issue":"Haematologica. 2022 Mar 17. doi: 10.3324\/haematol.2021.279857. Online ahead of print.","author":"Kudo K, Toki T, Kanezaki R, Tanaka T, Kamio T, Sato T, Sasaki S, Imamura M, Imai C, Ando K, Kakuda H, Doi T, Kawaguchi H, Irie M, Sasahara Y, Tamura A, Hasegawa D, Itakura Y, Watanabe K, Sakamoto K, Shioda Y, Kato M, Kudo K, Fukano R, Sato A, Yagasaki H, Kanegane H, Kato I, Umeda K, Adachi S, Kataoka T, Kurose A, Nakazawa A, Terui K, Ito E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35295077"},{"title01":"Registries in immune thrombocytopenia (ITP) in Europe: the European Research Consortium on ITP (ERCI) network","title02":"Registries in immune thrombocytopenia (ITP) in Europe: the European Research Consortium on ITP (ERCI) network","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 18. doi: 10.1111\/bjh.18111. Online ahead of print.","author":"Moulis G, Cooper N, Ghanima W, Gonz\u00e1lez-L\u00f3pez T, K\u00fchne T, Lozano ML, Michel M, Provan D, Zaja F, Aladjidi N, Christiansen CF, Frederiksen H, Grainger J, McDonald V, Robinson S, Schifferli A, Rodeghiero F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35303315"},{"title01":"Association of metformin treatment and outcome in adult patients with ITP and pre-existing T2DM","title02":"Association of metformin treatment and outcome in adult patients with ITP and pre-existing T2DM","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 14. doi: 10.1111\/bjh.18121. Online ahead of print.","author":"Li C, Sun M, Li R, Wang S, Shao L, Xu M, Yao M, Wang L, Hou M, Feng Q, Peng J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35288929"},{"title01":"Vaccinations and ITP: keep on track(ing)","title02":"Vaccinations and ITP: keep on track(ing)","journal":"Blood","issue":"2022 Mar 10;139(10):1437-1438.","author":"Bakchoul T, Singh A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35267007"},{"title01":"Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3\/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031","title02":"Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3<\/i>\/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Mar 29:JCO2101612. doi: 10.1200\/JCO.21.01612. Online ahead of print.","author":"Pollard JA, Alonzo TA, Gerbing R, Brown P, Fox E, Choi J, Fisher B, Hirsch B, Kahwash S, Getz K, Levine J, Brodersen LE, Loken MR, Raimondi S, Tarlock K, Wood A, Sung L, Kolb EA, Gamis A, Meshinchi S, Aplenc R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35349331"},{"title01":"Prognostic implications of the detection of measurable residual disease and mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA","title02":"Prognostic implications of the detection of measurable residual disease and mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 18. doi: 10.1111\/bjh.18143. Online ahead of print.","author":"Wang J, Jiang H, Jing Y, Su L, Liu D, Zhou D, Wang J, Liu H, Ruan GR, Gao S, Huang XJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35303314"},{"title01":"Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia","title02":"Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 21. doi: 10.1111\/bjh.18093. Online ahead of print.","author":"Valtis YK, Place AE, Silverman LB, Vrooman LM, DeAngelo DJ, Luskin MR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35312041"},{"title01":"Updated revision of the British Society of Haematology guidelines for chronic lymphocytic leukaemia","title02":"Updated revision of the British Society of Haematology guidelines for chronic lymphocytic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 21. doi: 10.1111\/bjh.18119. Online ahead of print.","author":"Moia R, Gaidano G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35313005"},{"title01":"Guideline for the treatment of chronic lymphocytic leukaemia","title02":"Guideline for the treatment of chronic lymphocytic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 21. doi: 10.1111\/bjh.18075. Online ahead of print.","author":"Walewska R, Parry-Jones N, Eyre TA, Follows G, Martinez-Calle N, McCarthy H, Parry H, Patten PEM, Riches JC, Hillmen P, Schuh AH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35313007"},{"title01":"Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy","title02":"Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 11. doi: 10.1111\/bjh.18129. Online ahead of print.","author":"Voso MT, Pandzic T, Falconi G, Den\u010di\u0107-Fekete M, De Bellis E, Scarfo L, Ljungstr\u00f6m V, Iskas M, Del Poeta G, Ranghetti P, Laidou S, Cristiano A, Plevova K, Imbergamo S, Engvall M, Zucchetto A, Salvetti C, Mauro FR, Stavroyianni N, Cavelier L, Ghia P, Stamatopoulos K, Fabiani E, Baliakas P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35277855"},{"title01":"Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study","title02":"Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 14. doi: 10.1111\/bjh.18090. Online ahead of print.","author":"Jobson D, McCormack CJ, Mar V, Tam C, Henderson MA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35286715"},{"title01":"Annexin A1- but CD10+ hairy cell leukemia","title02":"Annexin A1- but CD10+ hairy cell leukemia","journal":"Blood","issue":"2022 Mar 24;139(12):1924.","author":"Wang HY, Heyman BM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35323876"},{"title01":"Do CARs finally hit the CLL road?","title02":"Do CARs finally hit the CLL road?","journal":"Blood","issue":"2022 Mar 24;139(12):1775-1776.","author":"Kater AP, Melenhorst JJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35323881"},{"title01":"Efficacy and safety of CD19-specific CAR T-cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL","title02":"Efficacy and safety of CD19-specific CAR T-cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL","journal":"Blood","issue":"Blood. 2022 Mar 25:blood.2021013733. doi: 10.1182\/blood.2021013733. Online ahead of print.","author":"Qi Y, Zhao M, Hu Y, Wang Y, Li P, Cao J, Shi M, Tan J, Zhang M, Xiao X, Xia J, Ma S, Qiao J, Yan Z, Li H, Pan B, Sang W, Li D, Li Z, Zhou J, Huang H, Liang A, Zheng J, Xu K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35338773"},{"title01":"Neutralization of SARS-CoV-2 Omicron after vaccination of myelodysplastic syndromes and acute myeloid leukemia patients","title02":"Neutralization of SARS-CoV-2 Omicron after vaccination of myelodysplastic syndromes and acute myeloid leukemia patients","journal":"Blood","issue":"Blood. 2022 Mar 28:blood.2022016087. doi: 10.1182\/blood.2022016087. Online ahead of print.","author":"Bellusci L, Grubbs G, Srivastava P, Nemeth MJ, Griffiths EA, Golding H, Khurana S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35344579"},{"title01":"Cost-effectiveness of liposomal cytarabine\/daunorubicin in patients with newly diagnosed acute myeloid leukemia","title02":"Cost-effectiveness of liposomal cytarabine\/daunorubicin in patients with newly diagnosed acute myeloid leukemia","journal":"Blood","issue":"2022 Mar 17;139(11):1766-1770.","author":"Bewersdorf JP, Patel KK, Goshua G, Shallis RM, Podoltsev NA, Huntington SF, Zeidan AM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35298594"},{"title01":"Geriatric assessment in older adults with AML","title02":"Geriatric assessment in older adults with AML","journal":"Blood","issue":"2022 Mar 17;139(11):1773.","author":",https:\/\/pubmed.ncbi.nlm.nih.gov\/35298596\"","url":null},{"title01":"Impact of diagnostic genetics on remission MRD and transplantation outcomes in older AML patients","title02":"Impact of diagnostic genetics on remission MRD and transplantation outcomes in older AML patients","journal":"Blood","issue":"Blood. 2022 Mar 14:blood.2021014520. doi: 10.1182\/blood.2021014520. Online ahead of print.","author":"Murdock HM, Kim HT, Denlinger N, Vachhani P, Hambley BC, Manning BS, Gier S, Cho C, Tsai HK, McCurdy SR, Ho VT, Koreth J, Soiffer RJ, Ritz J, Carroll MP, Vasu S, Perales MA, Wang ES, Gondek LP, Devine SM, Alyea EP, Lindsley RC, Gibson CJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35286378"},{"title01":"Response-Adapted Postinduction Strategy in Follicular Lymphoma","title02":"Response-Adapted Postinduction Strategy in Follicular Lymphoma","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Mar 11:JCO2102818. doi: 10.1200\/JCO.21.02818. Online ahead of print.","author":"Shibusawa M, Kusumi E, Murakami J, Tanimoto T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35275704"},{"title01":"Children’s Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma","title02":"Children’s Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Mar 10:JCO2102678. doi: 10.1200\/JCO.21.02678. Online ahead of print.","author":"Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, Annett RD, Archer JH, Asselin BL, August KJ, Cho SY, Dunsmore KP, Fisher BT, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju AI, Lam A, Messinger YH, Miles RR, Okada M, Patel SI, Schafer ES, Schechter T, Singh N, Steele AC, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay P, Bollard CM, Loh ML, Hunger SP, Raetz EA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35271306"},{"title01":"Distinct genetic alterations in Burkitt-like lymphoma with 11q aberration and Burkitt lymphoma: a novel case report of composite lymphoma","title02":"Distinct genetic alterations in Burkitt-like lymphoma with 11q aberration and Burkitt lymphoma: a novel case report of composite lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Mar 31. doi: 10.3324\/haematol.2021.280543. Online ahead of print.","author":"Kim M, Hwang HS, Yoon DH, Chun SM, Go H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35354255"},{"title01":"Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO\/FIL study","title02":"Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO\/FIL study","journal":"Haematologica","issue":"Haematologica. 2022 Mar 24. doi: 10.3324\/haematol.2021.279426. Online ahead of print.","author":"Garc\u00eda-Sancho AM, Bellei M, L\u00f3pez-Parra M, Gritti G, Cort\u00e9s M, Novelli S, Panizo C, Petrucci L, Guti\u00e9rrez A, Dlouhy I, Bastos-Oreiro M, Sancho JM, Ram\u00edrez MJ, Moraleda JM, Carrillo E, Jim\u00e9nez-Ubieto AI, Jarque I, Orsucci L, Garc\u00eda-Torres E, Montalb\u00e1n C, Dodero A, Arranz R, De Las Heras N, Pascual MJ, L\u00f3pez-Jim\u00e9nez J, Spina M, Re A, De Villambrosia SG, Bobillo S, Federico M, Caballero D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35320921"},{"title01":"Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory\/relapse diffuse large B cell lymphoma","title02":"Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory\/relapse diffuse large B cell lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Mar 24. doi: 10.3324\/haematol.2021.280464. Online ahead of print.","author":"Quivoron C, Tarabay A, Michot JM, Pag\u00e8s A, Lecourt H, Aup\u00e9rin A, Danu A, Lazarovici J, Rossignol J, Ghez D, Dartigues P, Verg\u00e9 V, Massard C, Camara-Clayette V, Ribrag V, Sarkozy C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35320922"},{"title01":"The IL32\/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition","title02":"The IL32\/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition","journal":"Haematologica","issue":"Haematologica. 2022 Mar 10. doi: 10.3324\/haematol.2021.279800. Online ahead of print.","author":"Decombis S, Papin A, Bellanger C, Sortais C, Dousset C, Le Bris Y, Riveron T, Blandin S, Hulin P, Tessoulin B, Rouel M, Le Gouill S, Moreau-Aubry A, Pellat-Deceunynck C, Chiron D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35263985"},{"title01":"Body size and risk of non-Hodgkin lymphoma by subtype: A pooled analysis from six prospective cohorts in the United States","title02":"Body size and risk of non-Hodgkin lymphoma by subtype: A pooled analysis from six prospective cohorts in the United States","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 29. doi: 10.1111\/bjh.18150. Online ahead of print.","author":"Teras LR, Bertrand KA, Deubler EL, Chao CR, Lacey JV Jr, Patel AV, Rosner BA, Shu YH, Wang K, Zhong C, Wang SS, Birmann BM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35348212"},{"title01":"Rare central nervous system lymphomas","title02":"Rare central nervous system lymphomas","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 16. doi: 10.1111\/bjh.18128. Online ahead of print.","author":"Kaji FA, Martinez-Calle N, Sovani V, Fox CP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35292959"},{"title01":"Checkpoint CD47 expression in classical Hodgkin lymphoma","title02":"Checkpoint CD47 expression in classical Hodgkin lymphoma","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 17. doi: 10.1111\/bjh.18137. Online ahead of print.","author":"Gholiha AR, Hollander P, L\u00f6f L, Glimelius I, Hedstrom G, Molin D, Hjalgrim H, Smedby KE, Hashemi J, Amini RM, Enblad G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35301709"},{"title01":"Ocular involvement in patients with primary central-nervous-system lymphoma: Analysis of a multicentre study in Spain","title02":"Ocular involvement in patients with primary central-nervous-system lymphoma: Analysis of a multicentre study in Spain","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 20. doi: 10.1111\/bjh.18148. Online ahead of print.","author":"Mercadal S, Ala\u00f1\u00e1 M, Barcel\u00f3 MI, Bruixola G, L\u00f3pez-Pereira P, Bobillo S, Dlouhy I, Agud RC, Molina EG, Mart\u00ednez P, Cacabelos P, Munta\u00f1ola A, Garc\u00eda-Catal\u00e1n G, Sancho JM, Campos I, Lado T, Salar A, Caballero AC, Sol\u00e9-Rodr\u00edguez M, Velasco R; Grupo Espa\u00f1ol de Linfomas y Trasplante Aut\u00f3logo de M\u00e9dula \u00d3sea (GELTAMO) and Grupo de Estudio de Neuro-Oftalmolog\u00eda de la Sociedad Espa\u00f1ola de Neurolog\u00eda (GENOSEN) group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35307813"},{"title01":"Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia","title02":"Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia","journal":"Leukemia","issue":"Leukemia. 2022 Mar 25. doi: 10.1038\/s41375-022-01522-3. Online ahead of print.","author":"Baccarani M, Bonifazi F, Soverini S, Castagnetti F, Gugliotta G, Saber W, Estrada-Merly N, Rosti G, Gale RP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35338251"},{"title01":"In vivo anti-tumor effect of PARP inhibition in IDH1\/2 mutant MDS\/AML resistant to targeted inhibitors of mutant IDH1\/2","title02":"In vivo anti-tumor effect of PARP inhibition in IDH1\/2 mutant MDS\/AML resistant to targeted inhibitors of mutant IDH1\/2","journal":"Leukemia","issue":"Leukemia. 2022 Mar 10. doi: 10.1038\/s41375-022-01536-x. Online ahead of print.","author":"Gbyli R, Song Y, Liu W, Gao Y, Biancon G, Chandhok NS, Wang X, Fu X, Patel A, Sundaram R, Tebaldi T, Mamillapalli P, Zeidan AM, Flavell RA, Prebet T, Bindra RS, Halene S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35273342"},{"title01":"Temporal changes in incidence of relapse and outcome after relapse of childhood acute lymphoblastic leukemia over three decades; a Nordic population-based cohort study","title02":"Temporal changes in incidence of relapse and outcome after relapse of childhood acute lymphoblastic leukemia over three decades; a Nordic population-based cohort study","journal":"Leukemia","issue":"Leukemia. 2022 Mar 21. doi: 10.1038\/s41375-022-01540-1. Online ahead of print.","author":"Jensen KS, Oskarsson T, L\u00e4hteenm\u00e4ki PM, Flaegstad T, J\u00f3nsson \u00d3G, Svenberg P, Schmiegelow K, Heyman M, Nor\u00e9n-Nystr\u00f6m U, Schr\u00f8der H, Albertsen BK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35314777"},{"title01":"Randomized phase II study of azacitidine \u00b1 lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)","title02":"Randomized phase II study of azacitidine \u00b1 lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)","journal":"Leukemia","issue":"Leukemia. 2022 Mar 11. doi: 10.1038\/s41375-022-01537-w. Online ahead of print.","author":"Rasmussen B, G\u00f6hring G, Bernard E, Nilsson L, Tobiasson M, J\u00e4dersten M, Garelius H, Dybedal I, Gr\u00f8nbaek K, Ejerblad E, Lorenz F, Flogeg\u00e5rd M, Marcher CW, \u00d6ster Fernstr\u00f6m A, Cavelier L, Papaemmanuil E, Ebeling F, Kittang AO, N\u00f8rgaard JM, Saft L, M\u00f6llg\u00e5rd L, Hellstr\u00f6m-Lindberg E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35277655"},{"title01":"Children’s Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma","title02":"Children’s Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Mar 10:JCO2102678. doi: 10.1200\/JCO.21.02678. Online ahead of print.","author":"Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, Annett RD, Archer JH, Asselin BL, August KJ, Cho SY, Dunsmore KP, Fisher BT, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju AI, Lam A, Messinger YH, Miles RR, Okada M, Patel SI, Schafer ES, Schechter T, Singh N, Steele AC, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay P, Bollard CM, Loh ML, Hunger SP, Raetz EA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35271306"},{"title01":"TAL1 cooperates with PI3K\/AKT pathway activation in T-cell acute lymphoblastic leukemia","title02":"TAL1 cooperates with PI3K\/AKT pathway activation in T-cell acute lymphoblastic leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Mar 31. doi: 10.3324\/haematol.2021.279718. Online ahead of print.","author":"Thielemans N, Demeyer S, Mentens N, Gielen O, Provost S, Cools J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35354248"},{"title01":"Acute central nervous system toxicity during treatment of pediatric acute lymphoblastic leukemia: phenotypes, risk factors and genotypes","title02":"Acute central nervous system toxicity during treatment of pediatric acute lymphoblastic leukemia: phenotypes, risk factors and genotypes","journal":"Haematologica","issue":"Haematologica. 2022 Mar 31. doi: 10.3324\/haematol.2021.280016. Online ahead of print.","author":"Anastasopoulou S, Nielsen RL, Als-Nielsen B, Banerjee J, Eriksson MA, Helenius M, Heyman MM, Johannsdottir IM, Jonsson OG, MacGregor S, Mateos MK, Mayoh C, Mikkel S, Myrberg IH, Niinim\u00e4ki R, Schmiegelow K, Taskinen M, Vaitkeviciene G, Warnqvist A, Wolthers B, Harila-Saari A, Ranta S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35354251"},{"title01":"The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era","title02":"The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era","journal":"Haematologica","issue":"Haematologica. 2022 Mar 31. doi: 10.3324\/haematol.2021.280501. Online ahead of print.","author":"Kockerols CCB, Geelen I, Levin MD, Janssen JJWM, Dinmohamed AG, Hoogendoorn M, Cornelissen JJ, Westerweel PE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35354254"},{"title01":"Clinical relevance of an objective – limit of detection – limit of quantification – based flow cytometry approach for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial","title02":"Clinical relevance of an objective – limit of detection – limit of quantification – based flow cytometry approach for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial","journal":"Haematologica","issue":"Haematologica. 2022 Mar 17. doi: 10.3324\/haematol.2021.279777. Online ahead of print.","author":"Buccisano F, Palmieri R, Piciocchi A, Arena V, Maurillo L, Del Principe MI, Paterno G, Irno-Consalvo MA, Ottone T, Divona M, Conti C, Fraboni D, Lavorgna S, Arcese W, Voso MT, Venditti A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35295076"},{"title01":"Syndromes predisposing to leukemia are a major cause of inherited cytopenias in children","title02":"Syndromes predisposing to leukemia are a major cause of inherited cytopenias in children","journal":"Haematologica","issue":"Haematologica. 2022 Mar 17. doi: 10.3324\/haematol.2021.280116. Online ahead of print.","author":"Gilad O, Dgany O, Noy-Lotan S, Krasnov T, Yacobovich J, Rabinowicz R, Goldberg T, Kuperman AA, Abu-Quider A, Miskin H, Kapelushnik N, Mandel-Shorer N, Shimony S, Harlev D, Ben-Ami T, Adam E, Levin C, Aviner S, Elhasid R, Berger-Achituv S, Chaitman-Yerushalmi L, Kodman Y, Oniashvilli N, Hameiri-Grosman M, Izraeli S, Tamary H, Steinberg-Shemer O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35295078"},{"title01":"A self-assembled leucine polymer sensitizes leukemic stem cells to chemotherapy by inhibiting autophagy in acute myeloid leukemia","title02":"A self-assembled leucine polymer sensitizes leukemic stem cells to chemotherapy by inhibiting autophagy in acute myeloid leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Mar 17. doi: 10.3324\/haematol.2021.280290. Online ahead of print.","author":"Xu X, Wang J, Tong T, Zhang W, Wang J, Ma W, Wang S, Zhou D, Wu J, Jiang L, Zhao M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35295079"},{"title01":"Delving the depths of MRD negativity in acute myeloid leukemia","title02":"Delving the depths of MRD negativity in acute myeloid leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Mar 17. doi: 10.3324\/haematol.2022.280747. Online ahead of print.","author":"Freeman SD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35295082"},{"title01":"Is it primary myelofibrosis or chronic megakaryocytic leukemia?","title02":"Is it primary myelofibrosis or chronic megakaryocytic leukemia?","journal":"Haematologica","issue":"Haematologica. 2022 Mar 17. doi: 10.3324\/haematol.2022.280838. Online ahead of print.","author":"Lichtman MA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35295083"},{"title01":"High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL","title02":"High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL","journal":"Haematologica","issue":"Haematologica. 2022 Mar 10. doi: 10.3324\/haematol.2021.280078. Online ahead of print.","author":"Cabannes-Hamy A, Brissot E, Leguay T, Huguet F, Chevallier P, Hunault M, Escoffre-Barbe M, Cluzeau T, Balsat M, Nguyen S, Pasquier F, Alexis M, Lheritier V, Pastoret C, Delabesse E, Clappier E, Dombret H, Boissel N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35263986"},{"title01":"Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia","title02":"Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 28. doi: 10.1111\/bjh.18152. Online ahead of print.","author":"Lynggaard LS, Vaitkeviciene G, Langenski\u00f6ld C, Lehmann AK, L\u00e4hteenm\u00e4ki PM, Lepik K, El Hariry I, Schmiegelow K, Albertsen BK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35344210"},{"title01":"Immunophenotypically defined stem cell subsets in paediatric AML are highly heterogeneous and demonstrate differences in BCL-2 expression by cytogenetic subgroups","title02":"Immunophenotypically defined stem cell subsets in paediatric AML are highly heterogeneous and demonstrate differences in BCL-2 expression by cytogenetic subgroups","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 17. doi: 10.1111\/bjh.18094. Online ahead of print.","author":"Petersen MA, Rosenberg CA, Br\u00f8ndum RF, Aggerholm A, Kjeldsen E, Rahbek O, Ludvigsen M, Hasle H, Roug AS, Bill M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35298835"},{"title01":"RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia","title02":"RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia","journal":"Leukemia","issue":"Leukemia. 2022 Mar 30. doi: 10.1038\/s41375-022-01541-0. Online ahead of print.","author":"Decroocq J, Birsen R, Montersino C, Chaskar P, Mano J, Poulain L, Friedrich C, Alary AS, Guermouche H, Sahal A, Fouquet G, Gotan\u00e8gre M, Simonetta F, Mouche S, Gestraud P, Lescure A, Del Nery E, Bosc C, Grenier A, Mazed F, Mondesir J, Chapuis N, Ho L, Boughalem A, Lelorc'h M, Gobeaux C, Fontenay M, Recher C, Vey N, Guill\u00e9 A, Birnbaum D, Hermine O, Radford-Weiss I, Tsantoulis P, Collette Y, Castellano R, Sarry JE, Pasmant E, Bouscary D, Kosmider O, Tamburini J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35354920"},{"title01":"Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group","title02":"Molecular heterogeneity and measurable residual disease of rare NPM1<\/i> mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group","journal":"Leukemia","issue":"Leukemia. 2022 Mar 7. doi: 10.1038\/s41375-022-01534-z. Online ahead of print.","author":"Fournier E, Heiblig M, Lespinasse C, Flandrin-Gresta P, Geay A, Miguet L, Fenwarth L, Vallat L, Soubeyrand B, Marceau-Renaut A, Plesa A, Preudhomme C, Sujobert P, Hayette S, Duployez N, Huet S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35256762"},{"title01":"Pseudo-mutant P53 is a unique phenotype of DNMT3A-mutated pre-leukemia","title02":"Pseudo-mutant P53 is a unique phenotype of DNMT3A<\/i>-mutated pre-leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Feb 24. doi: 10.3324\/haematol.2021.280329. Online ahead of print.","author":"Tuval A, Brilon Y, Azogy H, Moskovitz Y, Leshkowitz D, Salame TM, Minden MD, Tal P, Rotter V, Oren M, Kaushansky N, Shlush LI.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35199506"},{"title01":"The three musketeers: uniting against CLL","title02":"The three musketeers: uniting against CLL","journal":"Blood","issue":"2022 Mar 3;139(9):1264-1265.","author":"Kwok M, Stankovic T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35238892"},{"title01":"A nonstick marrow may help to fry leukemia","title02":"A nonstick marrow may help to fry leukemia","journal":"Blood","issue":"2022 Feb 24;139(8):1119-1121.","author":"Maiti A, Daver NG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35201330"},{"title01":"And the germline beat (AML) goes on","title02":"And the germline beat (AML) goes on","journal":"Blood","issue":"2022 Feb 24;139(8):1126-1128.","author":"Brown AL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35201331"},{"title01":"Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML","title02":"Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML","journal":"Blood","issue":"Blood. 2022 Mar 1:blood.2021014671. doi: 10.1182\/blood.2021014671. Online ahead of print.","author":"Tyagi A, Ly S, El-Dana F, Yuan B, Jaggupilli A, Grimm S, Konopleva MY, B\u00fchring HJ, Battula VL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35231101"},{"title01":"Causes of death of patients with follicular lymphoma in the Netherlands by stage and age groups: a population-based study in the pre- and post-rituximab era","title02":"Causes of death of patients with follicular lymphoma in the Netherlands by stage and age groups: a population-based study in the pre- and post-rituximab era","journal":"Leukemia","issue":"Leukemia. 2022 Mar 4. doi: 10.1038\/s41375-022-01535-y. Online ahead of print.","author":"Dinnessen MAW, Maas CCHM, Tonino SH, Visser O, Posthuma EFM, Blijlevens NMA, Kersten MJ, Lugtenburg PJ, Dinmohamed AG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35246605"},{"title01":"Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study","title02":"Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study","journal":"Haematologica","issue":"Haematologica. 2022 Mar 3. doi: 10.3324\/haematol.2021.280257. Online ahead of print.","author":"Dourthe ME, Phulpin A, Auperin A, Bosq J, Couec ML, Dartigues P, Ducassou S, Garnier N, Haouy S, Leblanc T, Leruste A, Paillard C, Rigaud C, Simonin M, Patte C, Minard-Colin V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35236054"},{"title01":"Rituximab-treated lymphoma patients develop strong CD8 T-cell responses following COVID-19 vaccination","title02":"Rituximab-treated lymphoma patients develop strong CD8 T-cell responses following COVID-19 vaccination","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 7. doi: 10.1111\/bjh.18149. Online ahead of print.","author":"Riise J, Meyer S, Blaas I, Chopra A, Tran TT, Delic-Sarac M, Hestdalen ML, Brodin E, Rustad EH, Dai KZ, Vaage JT, Nissen-Meyer LSH, Sund F, Wader KF, Bjornevik AT, Meyer PA, Nygaard GO, K\u00f6nig M, Smeland S, Lund-Johansen F, Olweus J, Kolstad A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35254660"},{"title01":"Navigating increasingly individualised Hodgkin lymphoma treatments to optimally balance risks and benefits","title02":"Navigating increasingly individualised Hodgkin lymphoma treatments to optimally balance risks and benefits","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 9. doi: 10.1111\/bjh.18130. Online ahead of print.","author":"Br\u00f6ckelmann PJ, Borchmann P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35262911"},{"title01":"Bone health and glucocorticoid-containing lymphoma therapy – a review of risk factors and preventative measures","title02":"Bone health and glucocorticoid-containing lymphoma therapy – a review of risk factors and preventative measures","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 2. doi: 10.1111\/bjh.18104. Online ahead of print.","author":"Eyre TA, Jensen P, Booth S, El-Galaly TC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35235226"},{"title01":"CAR T cells and autologous transplantation can coexist for DLBCL","title02":"CAR T cells and autologous transplantation can coexist for DLBCL","journal":"Blood","issue":"2022 Mar 3;139(9):1266-1267.","author":"Lulla PD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35238887"},{"title01":"Chronic GVHD of the CNS","title02":"Chronic GVHD of the CNS","journal":"Blood","issue":"2022 Mar 3;139(9):1271-1272.","author":"Chen BJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35238888"},{"title01":"The RIG-I-NRF2 axis regulates the mesenchymal stromal niche for bone marrow transplantation","title02":"The RIG-I-NRF2 axis regulates the mesenchymal stromal niche for bone marrow transplantation","journal":"Blood","issue":"Blood. 2022 Mar 8:blood.2021013048. doi: 10.1182\/blood.2021013048. Online ahead of print.","author":"Lou Q, Jiang K, Xu Q, Yuan L, Xie S, Pan Y, Chen J, Wu J, Zhu J, Jiang L, Zhao M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35259210"},{"title01":"BET-bromodomain and EZH2 inhibitor treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes","title02":"BET-bromodomain and EZH2 inhibitor treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes","journal":"Blood","issue":"Blood. 2022 Feb 28:blood.2021014557. doi: 10.1182\/blood.2021014557. Online ahead of print.","author":"Zaiken MC, Flynn R, Paz KG, Rhee SY, Jin S, Mohamed FA, Saha A, Thangavelu G, Park PMC, Hemming ML, Sage PT, Sharpe AH, DuPage M, Bluestone JA, Panoskaltsis-Mortari A, Cutler CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Luznik L, Maillard I, Hill GR, MacDonald KP, Munn DH, Serody JS, Murphy WJ, Kean LS, Zhang Y, Bradner JE, Qi J, Blazar BR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35226736"},{"title01":"Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic haematopoietic stem cell transplantation","title02":"Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic haematopoietic stem cell transplantation","journal":"Haematologica","issue":"Haematologica. 2022 Mar 3. doi: 10.3324\/haematol.2021.280494. Online ahead of print.","author":"Einarsdottir S, Martner A, Nicklasson M, Wiktorin HG, Arabpour M, T\u00f6rnell A, Vaht K, Waldenstr\u00f6m J, Ringlander J, Bergstr\u00f6m T, Brune M, Hellstrand K, Ljungman P, Lagging M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35236057"},{"title01":"Effects of eltrombopag on mesenchymal stem cells in immune thrombocytopenia purpura","title02":"Effects of eltrombopag on mesenchymal stem cells in immune thrombocytopenia purpura","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 4. doi: 10.1111\/bjh.18101. Online ahead of print.","author":"Will B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35245400"},{"title01":"PP2A activation targets AML stem cells","title02":"PP2A activation targets AML stem cells","journal":"Blood","issue":"2022 Mar 3;139(9):1267-1269.","author":"Verrills NM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35238886"},{"title01":"How I Treat with Maintenance Therapy after Allogeneic HCT","title02":"How I Treat with Maintenance Therapy after Allogeneic HCT","journal":"Blood","issue":"Blood. 2022 Mar 1:blood.2021012412. doi: 10.1182\/blood.2021012412. Online ahead of print.","author":"DeFilipp Z, Chen YB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35231083"},{"title01":"Age-dependent effects of Igf2bp2 on gene regulation, function, and aging of hematopoietic stem cells in mice","title02":"Age-dependent effects of Igf2bp2<\/i> on gene regulation, function, and aging of hematopoietic stem cells in mice","journal":"Blood","issue":"Blood. 2022 Mar 1:blood.2021012197. doi: 10.1182\/blood.2021012197. Online ahead of print.","author":"Suo M, Rommelfanger MK, Chen Y, Amro EM, Han B, Chen Z, Szafranski K, Chakkarappan SR, Boehm BO, MacLean AL, Rudolph KL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35231105"},{"title01":"Filling the data gaps on sickle cell anaemia in sub-Saharan Africa","title02":"Filling the data gaps on sickle cell anaemia in sub-Saharan Africa","journal":"Lancet Haematol","issue":"2022 Mar;9(3):e172-e173.","author":"Williams TN.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35240070"},{"title01":"Estimating the risk of child mortality attributable to sickle cell anaemia in sub-Saharan Africa: a retrospective, multicentre, case-control study","title02":"Estimating the risk of child mortality attributable to sickle cell anaemia in sub-Saharan Africa: a retrospective, multicentre, case-control study","journal":"Lancet Haematol","issue":"2022 Mar;9(3):e208-e216.","author":"Ranque B, Kitenge R, Ndiaye DD, Ba MD, Adjoumani L, Traore H, Coulibaly C, Guindo A, Boidy K, Mbuyi D, Ly ID, Offredo L, Diallo DA, Tolo A, Kafando E, Tshilolo L, Diagne I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35240076"},{"title01":"Transplantation for Fanconi anaemia: lessons learned from Brazil","title02":"Transplantation for Fanconi anaemia: lessons learned from Brazil","journal":"Lancet Haematol","issue":"2022 Mar;9(3):e228-e236.","author":"Bonfim C, Nichele S, Loth G, Funke VAM, Nabhan SK, Pillonetto DV, Lima ACM, Pasquini R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35240077"},{"title01":"Autoimmune disease and sickle cell anaemia: ‘Intersecting pathways and differential diagnosis’","title02":"Autoimmune disease and sickle cell anaemia: ‘Intersecting pathways and differential diagnosis’","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 4. doi: 10.1111\/bjh.18109. Online ahead of print.","author":"Piccin A, O'Connor-Byrne N, Daves M, Lynch K, Farshbaf AD, Martin-Loeches I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35244209"},{"title01":"Anemia in the pediatric patient","title02":"Anemia in the pediatric patient","journal":"Blood","issue":"Blood. 2022 Feb 25:blood.2020006479. doi: 10.1182\/blood.2020006479. Online ahead of print.","author":"Gallagher PG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35213686"},{"title01":"HEATR3 variants impair nuclear import of uL18 (RPL5) and drive Diamond-Blackfan anemia","title02":"HEATR3<\/i> variants impair nuclear import of uL18 (RPL5) and drive Diamond-Blackfan anemia","journal":"Blood","issue":"Blood. 2022 Feb 25:blood.2021011846. doi: 10.1182\/blood.2021011846. Online ahead of print.","author":"O'Donohue MF, Da Costa LM, Lezzerini M, Unal S, Joret C, Bartels M, Brilstra E, Scheijde-Vermeulen M, Wacheul L, De Keersmaecker K, Vereecke S, Labarque V, Saby MJ, LeFevre SD, Platon J, Montel-Lehry N, Laugero N, Lacazette E, van Gassen K, Houtkooper RH, Simsek-Kiper PO, Leblanc TM, Yarali N, Cetinkaya A, Akarsu NA, Gleizes PE, Lafontaine DLJ, MacInnes AW.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35213692"},{"title01":"A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia","title02":"A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia","journal":"Blood","issue":"Blood. 2022 Feb 28:blood.2021013674. doi: 10.1182\/blood.2021013674. Online ahead of print.","author":"Rees DC, Kilinc Y, Unal S, Dampier CD, Pace B, Kaya B, Trompeter S, Odame I, Mahlangu J, Unal S, Brent J, Grosse R, Fuh B, Inusa BP, Koren A, Leblebisatan G, Levin C, McNamara E, Meiser K, Hom D, Oliver SJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35226723"},{"title01":"Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia","title02":"Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia","journal":"Haematologica","issue":"Haematologica. 2022 Feb 24. doi: 10.3324\/haematol.2021.279751. Online ahead of print.","author":"Zheng SS, Ahmadi Z, Leung HHL, Wong R, Yan F, Perdomo JS, Chong BH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35199503"},{"title01":"Effects of eltrombopag on mesenchymal stem cells in immune thrombocytopenia purpura","title02":"Effects of eltrombopag on mesenchymal stem cells in immune thrombocytopenia purpura","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 4. doi: 10.1111\/bjh.18101. Online ahead of print.","author":"Will B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35245400"},{"title01":"Natural history of PF4 antibodies in vaccine induced immune thrombocytopenia and thrombosis","title02":"Natural history of PF4 antibodies in vaccine induced immune thrombocytopenia and thrombosis","journal":"Blood","issue":"Blood. 2022 Mar 9:blood.2021014684. doi: 10.1182\/blood.2021014684. Online ahead of print.","author":"Craven B, Lester WA, Boyce S, Thomas W, Kanny A, Davies C, Pavord S, Hermans J, Makris M, Bart-Smith E, Arnott S, Hunt BJ, Chudakou P, Calvert A, Singh D, Scully M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35263420"},{"title01":"Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication","title02":"Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication","journal":"Leukemia","issue":"Leukemia. 2022 Mar 4. doi: 10.1038\/s41375-022-01530-3. Online ahead of print.","author":"Moretti S, Abdel-Aziz AK, Ceccacci E, Pallavicini I, Santoro F, de Th\u00e9 H, Minucci S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35246604"},{"title01":"Chronic lymphocytic leukaemia therapy: is less more?","title02":"Chronic lymphocytic leukaemia therapy: is less more?","journal":"Lancet Haematol","issue":"2022 Mar;9(3):e169-e171.","author":"Walter HS, Dyer MJS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35240069"},{"title01":"Is acute myeloid leukaemia maintenance therapy necessary?","title02":"Is acute myeloid leukaemia maintenance therapy necessary?","journal":"Lancet Haematol","issue":"2022 Mar;9(3):e177-e178.","author":"Ravandi F, Lancet J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35240073"},{"title01":"Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139\/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial","title02":"Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139\/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial","journal":"Lancet Haematol","issue":"2022 Mar;9(3):e190-e199.","author":"Kersting S, Dubois J, Nasserinejad K, Dobber JA, Mellink C, van der Kevie-Kersemaekers AF, Evers LM, de Boer F, Koene HR, Schreurs J, van der Klift M, Velders GA, van der Spek E, van der Straaten HM, Hoogendoorn M, van Gelder M, Posthuma EFM, Visser HPJ, Houtenbos I, Idink CAM, Issa DE, Dompeling EC, van Zaanen HCT, Veelken H, Levenga H, Tick LW, Terpstra WE, Tonino SH, Boyer M, Mobasher M, Levin MD, Kater AP; HOVON CLL study group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35240075"},{"title01":"Do liberal thresholds for red cell transfusion result in improved quality of life for patients undergoing intensive chemotherapy for acute myeloid leukemia? A randomized cross over feasibility study","title02":"Do liberal thresholds for red cell transfusion result in improved quality of life for patients undergoing intensive chemotherapy for acute myeloid leukemia? A randomized cross over feasibility study","journal":"Haematologica","issue":"Haematologica. 2022 Feb 24. doi: 10.3324\/haematol.2021.279867. Online ahead of print.","author":"Morton S, Sekhar M, Smethurst H, Mora A, Hodge RL, Hudson CL, Parsons J, Hopkins V, Stanworth SJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35199504"},{"title01":"Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study","title02":"Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study","journal":"Haematologica","issue":"Haematologica. 2022 Feb 24. doi: 10.3324\/haematol.2021.280325. Online ahead of print.","author":"Innocenti I, Reda G, Visentin A, Coscia M, Motta M, Murru R, Moia R, Gentile M, Pennese E, Quaglia FM, Albano F, Cassin R, Deodato M, Ielo C, Frustaci AM, Piciocchi A, Rughini A, Arena V, Di Sevo D, Tomasso A, Autore F, Del Poeta G, Scarf\u00f2 L, Mauro FR, Tedeschi A, Trentin L, Pompili M, Fo\u00e0 R, Ghia P, Cuneo A, Laurenti L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35199505"},{"title01":"Diagnosis of acute promyelocytic leukemia based on routine biological parameters using machine learning","title02":"Diagnosis of acute promyelocytic leukemia based on routine biological parameters using machine learning","journal":"Haematologica","issue":"Haematologica. 2022 Feb 24. doi: 10.3324\/haematol.2022.280406. Online ahead of print.","author":"Cheli E, Chevalier S, Kosmider O, Eveillard M, Chapuis N, Plesa A, Heiblig M, Andre L, Pouget J, Mossuz P, Theisen O, Alcazer V, Gugenheim D, Autexier N, Sujobert P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35199507"},{"title01":"How I diagnose and treat chronic myelomonocytic leukemia","title02":"How I diagnose and treat chronic myelomonocytic leukemia","journal":"Haematologica","issue":"Haematologica. 2022 Mar 3. doi: 10.3324\/haematol.2021.279500. Online ahead of print.","author":"Patnaik MM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35236051"},{"title01":"Decitabine salvage for Tumor Protein P53-mutated, relapsed\/refractory acute myeloid leukemia after cytotoxic induction therapy","title02":"Decitabine salvage for Tumor Protein P53-mutated, relapsed\/refractory acute myeloid leukemia after cytotoxic induction therapy","journal":"Haematologica","issue":"Haematologica. 2022 Mar 3. doi: 10.3324\/haematol.2021.280153. Online ahead of print.","author":"Ferraro F, Gruszczynska A, Ruzinova MB, Miller CA, Percival ME, Uy GL, Pusic I, Jacoby MA, Christopher MJ, Kim MY, Westervelt P, Cashen AF, Schroeder MA, DiPersio JF, Abboud CN, Wartman LD, Gao F, Link DC, Ley TJ, Welch JS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35236053"},{"title01":"Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechanisms. An index case","title02":"Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechanisms. An index case","journal":"Haematologica","issue":"Haematologica. 2022 Mar 3. doi: 10.3324\/haematol.2021.280393. Online ahead of print.","author":"Sk\u00e5nland SS, Inngjerdingen M, Bendiksen H, York J, Spetalen S, Munthe LA, Tj\u00f8nnfjord GE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35236056"},{"title01":"International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia","title02":"International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 7. doi: 10.1111\/bjh.18072. Online ahead of print.","author":"Oerlemans S, Efficace F, Kieffer JM, Kyriakou C, Xochelli A, Levedahl K, Petranovic D, Borges FC, Bredart A, Shamieh O, Gziskevicius L, Lehmann J, Scholz CW, Caocci G, Molica S, Stamatopoulos K, Panteliadou AK, Papaioannou M, Alrjoob W, Baliakas P, Rosenquist R, Malak S, Miranda A, Cocks K, van de Poll-Franse L; EORTC Quality of Life\u00a0Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35255152"},{"title01":"Health-related quality of life for patients with chronic lymphocytic leukaemia – A critical outcome measure in the era of highly effective therapies","title02":"Health-related quality of life for patients with chronic lymphocytic leukaemia – A critical outcome measure in the era of highly effective therapies","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 8. doi: 10.1111\/bjh.18118. Online ahead of print.","author":"Lew TE, Anderson MA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35262916"},{"title01":"Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia","title02":"Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 27. doi: 10.1111\/bjh.18105. Online ahead of print.","author":"Jacoby E, Bielorai B, Hutt D, Itzhaki O, Adam E, Bar D, Besser MJ, Toren A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35224724"},{"title01":"Pediatric B-acute lymphoblastic leukemia presenting with a mass: an underrecognized association","title02":"Pediatric B-acute lymphoblastic leukemia presenting with a mass: an underrecognized association","journal":"Blood","issue":"2022 Mar 3;139(9):1423.","author":"Stivers N, Afify Z.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35238884"},{"title01":"PP2A activation targets AML stem cells","title02":"PP2A activation targets AML stem cells","journal":"Blood","issue":"2022 Mar 3;139(9):1267-1269.","author":"Verrills NM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35238886"},{"title01":"CAR T cells and autologous transplantation can coexist for DLBCL","title02":"CAR T cells and autologous transplantation can coexist for DLBCL","journal":"Blood","issue":"2022 Mar 3;139(9):1266-1267.","author":"Lulla PD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35238887"},{"title01":"CAR T-cells as a second-line therapy of large B-cell lymphoma: A paradigm shift?","title02":"CAR T-cells as a second-line therapy of large B-cell lymphoma: A paradigm shift?","journal":"Blood","issue":"Blood. 2022 Mar 3:blood.2022015789. doi: 10.1182\/blood.2022015789. Online ahead of print.","author":"Westin JR, Sehn L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35240677"},{"title01":"R-CHOP in DLBCL: priming for success","title02":"R-CHOP in DLBCL: priming for success","journal":"Blood","issue":"2022 Feb 24;139(8):1121-1122.","author":"Hertzberg M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35201332"},{"title01":"Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma","title02":"Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Mar 8:JCO2102257. doi: 10.1200\/JCO.21.02257. Online ahead of print.","author":"Nooka AK, Shanmugasundaram U, Cheedarla N, Verkerke H, Edara VV, Valanparambil R, Kaufman JL, Hofmeister CC, Joseph NS, Lonial S, Azeem M, Manalo J, Switchenko JM, Chang A, Linderman SL, Roback JD, Dhodapkar KM, Ahmed R, Suthar MS, Neish AS, Dhodapkar MV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35259002"},{"title01":"Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials","title02":"Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 28. doi: 10.1111\/bjh.18102. Online ahead of print.","author":"Soomro MA, Hoffman J, Goodman AM, Sborov DW, Mohyuddin GR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35229286"},{"title01":"SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma","title02":"SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma","journal":"Blood","issue":"2022 Feb 24;139(8):1160-1176.","author":"Kassem S, Diallo BK, El-Murr N, Carri\u00e9 N, Tang A, Fournier A, Bonnevaux H, Nicolazzi C, Cuisinier M, Arnould I, Sidhu SS, Corre J, Avet-Loiseau H, Teillaud JL, van de Velde H, Wiederschain D, Chiron M, Martinet L, Virone-Oddos A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35201323"},{"title01":"Transplantation for Fanconi anaemia: lessons learned from Brazil","title02":"Transplantation for Fanconi anaemia: lessons learned from Brazil","journal":"Lancet Haematol","issue":"2022 Mar;9(3):e228-e236.","author":"Bonfim C, Nichele S, Loth G, Funke VAM, Nabhan SK, Pillonetto DV, Lima ACM, Pasquini R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35240077"},{"title01":"Trends in Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplantation Over Three Decades: A BMTSS Report","title02":"Trends in Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplantation Over Three Decades: A BMTSS Report","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Mar 9:JCO2102372. doi: 10.1200\/JCO.21.02372. Online ahead of print.","author":"Bhatia S, Dai C, Landier W, Hageman L, Wu J, Schlichting E, Siler A, Funk E, Hicks J, Lim S, Balas N, Bosworth A, Te HS, Francisco L, Bhatia R, Salzman D, Goldman FD, Forman SJ, Weisdorf DJ, Wong FL, Armenian SH, Arora M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35263165"},{"title01":"Na\u00efve T-Cell Depletion to Prevent GVHD: Searching for a Better Mousetrap","title02":"Na\u00efve T-Cell Depletion to Prevent GVHD: Searching for a Better Mousetrap","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Feb 25:JCO2200105. doi: 10.1200\/JCO.22.00105. Online ahead of print.","author":"Soiffer RJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35213234"},{"title01":"Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic haematopoietic stem cell transplantation","title02":"Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic haematopoietic stem cell transplantation","journal":"Haematologica","issue":"Haematologica. 2022 Mar 3. doi: 10.3324\/haematol.2021.280494. Online ahead of print.","author":"Einarsdottir S, Martner A, Nicklasson M, Wiktorin HG, Arabpour M, T\u00f6rnell A, Vaht K, Waldenstr\u00f6m J, Ringlander J, Bergstr\u00f6m T, Brune M, Hellstrand K, Ljungman P, Lagging M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35236057"},{"title01":"Low incidence of hyperacute graft-versus-host disease (GVHD) with effective GVHD prophylaxis based on anti-thymocyte globulin","title02":"Low incidence of hyperacute graft-versus-host disease (GVHD) with effective GVHD prophylaxis based on anti-thymocyte globulin","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 4. doi: 10.1111\/bjh.18099. Online ahead of print.","author":"Radici V, Stocker N, Dulery R, Brissot E, Bannet A, van de Wyngaert Z, Sestili S, Belhocine R, Bonin A, Ledraa T, Mohty M, Malard F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35245388"},{"title01":"Incidence and outcomes of post-transplant lymphoproliferative disease after 5365 solid-organ transplants over a 20-year period at two UK transplant centres","title02":"Incidence and outcomes of post-transplant lymphoproliferative disease after 5365 solid-organ transplants over a 20-year period at two UK transplant centres","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Mar 2. doi: 10.1111\/bjh.18065. Online ahead of print.","author":"Santarsieri A, Rudge JF, Amin I, Gelson W, Parmar J, Pettit S, Sharkey L, Uttenthal BJ, Follows GA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35235680"},{"title01":"Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent","title02":"Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 16. doi: 10.1111\/bjh.18051. Online ahead of print.","author":"On S, Rath CG, Lan M, Wu B, Lau KM, Cheung E, Alegria W, Young R, Tan M, Kim C, Phun J, Patel N, Mannis G, Logan AC, Kennedy V, Goodman A, Taplitz RA, Young PA, Wen R, Saunders IM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35174480"},{"title01":"Adult T-cell leukemia: genomic analysis","title02":"Adult T-cell leukemia: genomic analysis","journal":"Blood","issue":"2022 Feb 17;139(7):953-954.","author":"Bangham CRM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35175323"},{"title01":"Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia","title02":"Enhancer retargeting of CDX2<\/i> and UBTF::ATXN7L3<\/i> define a subtype of high-risk B-progenitor acute lymphoblastic leukemia","journal":"Blood","issue":"Blood. 2022 Feb 22:blood.2022015444. doi: 10.1182\/blood.2022015444. Online ahead of print.","author":"Kimura S, Montefiori L, Iacobucci I, Zhao Y, Gao Q, Paietta EM, Haferlach C, Laird AD, Mead PE, Gu Z, Stock W, Litzow MR, Rowe JM, Luger SM, Hunger SP, Ryland G, Schmidt BM, Ekert PG, Oshlack A, Grimmond S, Rehn J, Breen J, Yeung DT, White DL, Aldoss I, Jabbour EJ, Pui CH, Meggendorfer M, Walter W, Kern W, Haferlach T, Brady SW, Zhang J, Roberts KG, Blombery P, Mullighan CG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35192684"},{"title01":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","title02":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","journal":"Blood","issue":"Blood. 2022 Feb 23:blood.2021014488. doi: 10.1182\/blood.2021014488. Online ahead of print.","author":"Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs RW, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson SR, Kuss BJ, Moreno C, Szafer-Glusman E, Russell K, Zhou C, Ninomoto JS, Dean JP, Wierda WG, Ghia P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35196370"},{"title01":"Fighting AML with its own weapons","title02":"Fighting AML with its own weapons","journal":"Blood","issue":"2022 Feb 10;139(6):807-809.","author":"Will B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35142855"},{"title01":"How I treat refractory\/relapsed hairy cell leukemia with BRAF inhibitors","title02":"How I treat refractory\/relapsed hairy cell leukemia with BRAF inhibitors","journal":"Blood","issue":"Blood. 2022 Feb 10:blood.2021013502. doi: 10.1182\/blood.2021013502. Online ahead of print.","author":"Falini B, De Carolis L, Tiacci E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35143639"},{"title01":"Primary Plasma Cell Leukemia displaying t(11;14) have specific genomic, transcriptional and clinical feature","title02":"Primary Plasma Cell Leukemia displaying t(11;14) have specific genomic, transcriptional and clinical feature","journal":"Blood","issue":"Blood. 2022 Feb 16:blood.2021014968. doi: 10.1182\/blood.2021014968. Online ahead of print.","author":"Cazaubiel T, Leleu X, Perrot A, Manier S, Buisson L, Mah\u00e9o S, Do Souto Ferreira L, Lannes R, Pavageau L, Hulin C, Marolleau JP, Voillat L, Belhadj K, Divoux M, Slama B, Brechignac S, Macro M, Stoppa AM, Laurence S, Orsini Piocelle F, Fontan J, Chretien ML, DeMarquette H, Mohty M, Schavgoulidze A, Avet-Loiseau H, Corre J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35171994"},{"title01":"Correction: Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials","title02":"Correction: Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials","journal":"Leukemia","issue":"Leukemia. 2022 Feb 18. doi: 10.1038\/s41375-022-01526-z. Online ahead of print.","author":"Dahl M, Husby S, Eskelund CW, Besenbacher S, Fjelstrup S, C\u00f4me C, Ek S, Kolstad A, R\u00e4ty R, Jerkeman M, Geisler CH, Kjems J, Kristensen LS, Gr\u00f8nb\u00e6k K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35181760"},{"title01":"Guideline for the first-line management of Classical Hodgkin Lymphoma – A British Society for Haematology guideline","title02":"Guideline for the first-line management of Classical Hodgkin Lymphoma – A British Society for Haematology guideline","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 22. doi: 10.1111\/bjh.18083. Online ahead of print.","author":"Follows GA, Barrington SF, Bhuller KS, Culligan DJ, Cutter DJ, Gallop-Evans E, Kassam S, Osborne W, Sadullah S, Townsend W, Uttenthal BJ, Collins GP; British Society for Haematology.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35191541"},{"title01":"Relapsed classic Hodgkin lymphoma with decreased CD30 expression after brentuximab and anti-CD30 CAR-T therapies","title02":"Relapsed classic Hodgkin lymphoma with decreased CD30 expression after brentuximab and anti-CD30 CAR-T therapies","journal":"Blood","issue":"2022 Feb 10;139(6):951.","author":"Kim DH, Vega F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35142847"},{"title01":"Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma: A phase I\/II clinical trial","title02":"Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma: A phase I\/II clinical trial","journal":"Blood","issue":"Blood. 2022 Feb 15:blood.2021014738. doi: 10.1182\/blood.2021014738. Online ahead of print.","author":"Frigault MJ, Dietrich J, Gallagher KME, Roschewski MJ, Jordan JT, Forst D, Plotkin SR, Cook D, Casey KS, Lindell KA, DePinho GD, Katsis K, Elder EL, Leick M, Choi BD, Horick N, Preffer F, Saylor M, McAfee S, O'Donnell PV, Spitzer TR, Dey BR, DeFilipp Z, El-Jawahri A, Batchelor TT, Maus MV, Chen YB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35167655"},{"title01":"Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio \u2265100","title02":"Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio \u2265100","journal":"Leukemia","issue":"Leukemia. 2022 Feb 21. doi: 10.1038\/s41375-022-01529-w. Online ahead of print.","author":"Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, Kumar SK.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35190659"},{"title01":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study","title02":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study","journal":"Lancet Oncol","issue":"2022 Feb 10:S1470-2045(22)00019-5. doi: 10.1016\/S1470-2045(22)00019-5. Online ahead of print.","author":"Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Malinge L, Dubin F, van de Velde H, Anderson KC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35151415"},{"title01":"All-oral triplet combination with ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible myeloma patients: final results of the phase 2 IFM study 2013-06","title02":"All-oral triplet combination with ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible myeloma patients: final results of the phase 2 IFM study 2013-06","journal":"Haematologica","issue":"Haematologica. 2022 Feb 17. doi: 10.3324\/haematol.2021.280394. Online ahead of print.","author":"Touzeau C, Perrot A, Roussel M, Karlin L, Benboubker L, Jacquet C, Mohty M, Facon T, Manier S, Chretien ML, Tiab M, Hulin C, Leleu X, Loiseau HA, Dejoie T, Planche L, Attal M, Moreau P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35172566"},{"title01":"Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019","title02":"Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 15. doi: 10.1111\/bjh.18025. Online ahead of print.","author":"Swan D, Hayden PJ, Eikema DJ, Koster L, Sauer S, Blaise D, Nicholson E, Rabin N, Touzeau C, Byrne J, Huynh A, Cornelissen JJ, Potter V, Forcade E, Parrish C, Gribben J, Chretien ML, Mielke S, Gedde-Dahl T, Rem\u00e9nyi P, Tsirigotis P, Garcia Gui\u00f1\u00f3n A, Beksac M, Sch\u00f6nland S, Yakoub-Agha I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35166376"},{"title01":"Serological response to SARS-CoV-2 mRNA-LNP vaccine in patients with multiple myeloma: a negative impact of CD38(+) Treg?","title02":"Serological response to SARS-CoV-2 mRNA-LNP vaccine in patients with multiple myeloma: a negative impact of CD38(+) Treg?","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 16. doi: 10.1111\/bjh.18110. Online ahead of print.","author":"Baron F, Caers J, Humblet-Baron S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35174478"},{"title01":"MRD end point in myeloma: ready for prime time?","title02":"MRD end point in myeloma: ready for prime time?","journal":"Blood","issue":"2022 Feb 10;139(6):799-802.","author":"Quach H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35142848"},{"title01":"Humoral immune-depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma","title02":"Humoral immune-depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Feb 17. doi: 10.3324\/haematol.2021.279561. Online ahead of print.","author":"Bouard L, Tessoulin B, Thieblemont C, Bouabdallah K, Gastinne T, Oberic L, Carras S, Delette C, Casasnovas O, Dartigeas C, Cacheux V, Masse S, Hermine O, Le Gouill S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35172560"},{"title01":"All-oral triplet combination with ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible myeloma patients: final results of the phase 2 IFM study 2013-06","title02":"All-oral triplet combination with ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible myeloma patients: final results of the phase 2 IFM study 2013-06","journal":"Haematologica","issue":"Haematologica. 2022 Feb 17. doi: 10.3324\/haematol.2021.280394. Online ahead of print.","author":"Touzeau C, Perrot A, Roussel M, Karlin L, Benboubker L, Jacquet C, Mohty M, Facon T, Manier S, Chretien ML, Tiab M, Hulin C, Leleu X, Loiseau HA, Dejoie T, Planche L, Attal M, Moreau P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35172566"},{"title01":"Leukaemic evolution of rare donor CSF3R germline mutation after umbilical cord blood transplant","title02":"Leukaemic evolution of rare donor CSF3R germline mutation after umbilical cord blood transplant","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 17. doi: 10.1111\/bjh.18078. Online ahead of print.","author":"Arnautou P, Quang VT, Konopacki J, Chevillon F, Bories D, Sloma I, Malfuson JV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35178734"},{"title01":"Radiological evidence of resolution of fatty marrow after bone marrow transplantation","title02":"Radiological evidence of resolution of fatty marrow after bone marrow transplantation","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 22. doi: 10.1111\/bjh.18068. Online ahead of print.","author":"Tamefusa K, Ochi M, Fujiwara K, Washio K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35191538"},{"title01":"Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019","title02":"Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 15. doi: 10.1111\/bjh.18025. Online ahead of print.","author":"Swan D, Hayden PJ, Eikema DJ, Koster L, Sauer S, Blaise D, Nicholson E, Rabin N, Touzeau C, Byrne J, Huynh A, Cornelissen JJ, Potter V, Forcade E, Parrish C, Gribben J, Chretien ML, Mielke S, Gedde-Dahl T, Rem\u00e9nyi P, Tsirigotis P, Garcia Gui\u00f1\u00f3n A, Beksac M, Sch\u00f6nland S, Yakoub-Agha I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35166376"},{"title01":"Dimethyl fumarate ameliorates graft-versus-host disease by inhibiting T-cell metabolism and immune responses through a reactive oxygen species-dependent mechanism","title02":"Dimethyl fumarate ameliorates graft-versus-host disease by inhibiting T-cell metabolism and immune responses through a reactive oxygen species-dependent mechanism","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 15. doi: 10.1111\/bjh.18082. Online ahead of print.","author":"Mashima K, Sato K, Ikeda T, Izawa J, Takayama N, Hayakawa H, Kawaguchi SI, Nakano H, Nagayama T, Umino K, Morita K, Tominaga K, Endo H, Kanda Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35170051"},{"title01":"Defects in mucosal immunity and nasopharyngeal dysbiosis in HSC transplanted SCID patients with IL2RG\/JAK3 deficiency","title02":"Defects in mucosal immunity and nasopharyngeal dysbiosis in HSC transplanted SCID patients with IL2RG\/JAK3 deficiency","journal":"Blood","issue":"Blood. 2022 Feb 14:blood.2021014654. doi: 10.1182\/blood.2021014654. Online ahead of print.","author":"Goncalves P, Doisne JM, Eri T, Charbit B, Bondet V, Posseme C, Llibre A, Milieu Int\u00e9rieur Consortium, Casrouge A, Lenoir C, Neven B, Duffy D, Fischer A, Di Santo JP; Milieu Int\u00e9rieur Consortium.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35157765"},{"title01":"IPO11 regulates the nuclear import of BZW1\/2 and is necessary for AML cells and stem cells","title02":"IPO11 regulates the nuclear import of BZW1\/2 and is necessary for AML cells and stem cells","journal":"Leukemia","issue":"Leukemia. 2022 Feb 12. doi: 10.1038\/s41375-022-01513-4. Online ahead of print.","author":"Nachmias B, Khan DH, Voisin V, Mer AS, Thomas GE, Segev N, St-Germain J, Hurren R, Gronda M, Botham A, Wang X, Maclean N, Seneviratne AK, Duong N, Xu C, Arruda A, Orouji E, Algouneh A, Hakem R, Shlush L, Minden MD, Raught B, Bader GD, Schimmer AD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35152270"},{"title01":"Human CD34(+) very small embryonic-like stem cells can give rise to endothelial colony-forming cells with a multistep differentiation strategy using UM171 and nicotinamide acid","title02":"Human CD34(+) very small embryonic-like stem cells can give rise to endothelial colony-forming cells with a multistep differentiation strategy using UM171 and nicotinamide acid","journal":"Leukemia","issue":"Leukemia. 2022 Feb 15. doi: 10.1038\/s41375-022-01517-0. Online ahead of print.","author":"Domingues A, Rossi E, Bujko K, Detriche G, Richez U, Blandinieres A, Kucia M, Ratajczak J, Smadja DM, Ratajczak MZ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35169243"},{"title01":"Humoral immune-depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma","title02":"Humoral immune-depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma","journal":"Haematologica","issue":"Haematologica. 2022 Feb 17. doi: 10.3324\/haematol.2021.279561. Online ahead of print.","author":"Bouard L, Tessoulin B, Thieblemont C, Bouabdallah K, Gastinne T, Oberic L, Carras S, Delette C, Casasnovas O, Dartigeas C, Cacheux V, Masse S, Hermine O, Le Gouill S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35172560"},{"title01":"Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019","title02":"Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 15. doi: 10.1111\/bjh.18025. Online ahead of print.","author":"Swan D, Hayden PJ, Eikema DJ, Koster L, Sauer S, Blaise D, Nicholson E, Rabin N, Touzeau C, Byrne J, Huynh A, Cornelissen JJ, Potter V, Forcade E, Parrish C, Gribben J, Chretien ML, Mielke S, Gedde-Dahl T, Rem\u00e9nyi P, Tsirigotis P, Garcia Gui\u00f1\u00f3n A, Beksac M, Sch\u00f6nland S, Yakoub-Agha I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35166376"},{"title01":"Defects in mucosal immunity and nasopharyngeal dysbiosis in HSC transplanted SCID patients with IL2RG\/JAK3 deficiency","title02":"Defects in mucosal immunity and nasopharyngeal dysbiosis in HSC transplanted SCID patients with IL2RG\/JAK3 deficiency","journal":"Blood","issue":"Blood. 2022 Feb 14:blood.2021014654. doi: 10.1182\/blood.2021014654. Online ahead of print.","author":"Goncalves P, Doisne JM, Eri T, Charbit B, Bondet V, Posseme C, Llibre A, Milieu Int\u00e9rieur Consortium, Casrouge A, Lenoir C, Neven B, Duffy D, Fischer A, Di Santo JP; Milieu Int\u00e9rieur Consortium.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35157765"},{"title01":"Fetal-like Hemoglobin in Sickle Cell Anemia","title02":"Fetal-like Hemoglobin in Sickle Cell Anemia","journal":"N Engl J Med","issue":"2022 Feb 17;386(7):689-691.","author":"Steinberg MH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35172060"},{"title01":"Unexplained iron overload with haemolytic anaemia should prompt looking for morphological changes in erythroid precursors","title02":"Unexplained iron overload with haemolytic anaemia should prompt looking for morphological changes in erythroid precursors","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 17. doi: 10.1111\/bjh.18030. Online ahead of print.","author":"Rieu JB, Largeaud L, Da Costa L, Cougoul P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35178704"},{"title01":"Fanconi anaemia: A syndrome with distinct subgroups","title02":"Fanconi anaemia: A syndrome with distinct subgroups","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 22. doi: 10.1111\/bjh.18091. Online ahead of print.","author":"Alter BP, Giri N, McReynolds LJ, Altintas B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35191533"},{"title01":"Iron chelation for myelofibrosis-related anaemia during treatment with a Janus kinase inhibitor","title02":"Iron chelation for myelofibrosis-related anaemia during treatment with a Janus kinase inhibitor","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 11. doi: 10.1111\/bjh.18071. Online ahead of print.","author":"Ross DM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35147212"},{"title01":"Voxelotor and albuminuria in adults with sickle cell anaemia","title02":"Voxelotor and albuminuria in adults with sickle cell anaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 14. doi: 10.1111\/bjh.18076. Online ahead of print.","author":"Han J, Molokie RE, Hussain F, Njoku F, Gordeuk VR, Saraf SL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35156191"},{"title01":"Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study","title02":"Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 18. doi: 10.1111\/bjh.18081. Online ahead of print.","author":"Al-Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Wojdyla M, Vredenburg M, Cuker A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35179784"},{"title01":"Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures","title02":"Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures","journal":"Leukemia","issue":"Leukemia. 2022 Feb 11. doi: 10.1038\/s41375-022-01519-y. Online ahead of print.","author":"Vaca AM, Ioannou N, Sivina M, Vlachonikola E, Clise-Dwyer K, Kim E, Li D, Ma Q, Ferrajoli A, Estrov Z, Wierda WG, Patten PEM, Ramsay AG, Burger JA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35149845"},{"title01":"IPO11 regulates the nuclear import of BZW1\/2 and is necessary for AML cells and stem cells","title02":"IPO11 regulates the nuclear import of BZW1\/2 and is necessary for AML cells and stem cells","journal":"Leukemia","issue":"Leukemia. 2022 Feb 12. doi: 10.1038\/s41375-022-01513-4. Online ahead of print.","author":"Nachmias B, Khan DH, Voisin V, Mer AS, Thomas GE, Segev N, St-Germain J, Hurren R, Gronda M, Botham A, Wang X, Maclean N, Seneviratne AK, Duong N, Xu C, Arruda A, Orouji E, Algouneh A, Hakem R, Shlush L, Minden MD, Raught B, Bader GD, Schimmer AD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35152270"},{"title01":"Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm","title02":"Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm","journal":"Leukemia","issue":"Leukemia. 2022 Feb 16. doi: 10.1038\/s41375-022-01524-1. Online ahead of print.","author":"Halpern AB, Othus M, Alcorn G, Ali Z, Garcia KA, Percival MM, Keel SB, Cassaday RD, Becker PS, Estey EH, Walter RB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35173273"},{"title01":"Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL","title02":"Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL","journal":"Leukemia","issue":"Leukemia. 2022 Feb 16. doi: 10.1038\/s41375-022-01516-1. Online ahead of print.","author":"Piya S, Yang Y, Bhattacharya S, Sharma P, Ma H, Mu H, He H, Ruvolo V, Baran N, Davis RE, Jain AK, Konopleava M, Kantarjian H, Andreeff M, You MJ, Borthakur G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35173274"},{"title01":"SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia","title02":"SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia","journal":"J Clin Oncol","issue":"J Clin Oncol. 2022 Feb 14:JCO2101766. doi: 10.1200\/JCO.21.01766. Online ahead of print.","author":"Advani AS, Moseley A, O'Dwyer KM, Wood BL, Fang M, Wieduwilt MJ, Aldoss I, Park JH, Klisovic RB, Baer MR, Stock W, Bhave RR, Othus M, Harvey RC, Willman CL, Litzow MR, Stone RM, Sharon E, Erba HP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35157496"},{"title01":"The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias","title02":"The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias","journal":"Haematologica","issue":"Haematologica. 2022 Feb 17. doi: 10.3324\/haematol.2021.279889. Online ahead of print.","author":"Paolillo R, Boulanger M, G\u00e2tel P, Gabellier L, De Toledo M, Temp\u00e9 D, Hallal R, Akl D, Moreaux J, Baik H, Gueret E, Recher C, Sarry JE, Cartron G, Piechaczyk M, Bossis G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35172562"},{"title01":"Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial","title02":"Outstanding outcomes in infants with KMT2A<\/i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial","journal":"Haematologica","issue":"Haematologica. 2022 Feb 17. doi: 10.3324\/haematol.2021.280146. Online ahead of print.","author":"Guest EM, Kairalla JA, Hilden JM, Dreyer ZE, Carroll AJ, Heerema NA, Wang CY, Devidas M, Gore L, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Borowitz M, Loh ML, Hunger SP, Brown PA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35172563"},{"title01":"NOX2: determinant of acute myeloid leukemia survival","title02":"NOX2: determinant of acute myeloid leukemia survival","journal":"Haematologica","issue":"Haematologica. 2022 Feb 17. doi: 10.3324\/haematol.2022.280677. Online ahead of print.","author":"Jones CL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35172567"},{"title01":"Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia","title02":"Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 15. doi: 10.1111\/bjh.18053. Online ahead of print.","author":"Gadi D, Griffith A, Wang Z, Tyekucheva S, Rai V, Fernandes SM, Machado JH, Munugalavadla V, Lederer J, Brown JR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35170759"},{"title01":"Multi-omics reveals mitochondrial metabolism proteins susceptible for drug discovery in AML","title02":"Multi-omics reveals mitochondrial metabolism proteins susceptible for drug discovery in AML","journal":"Leukemia","issue":"Leukemia. 2022 Feb 17. doi: 10.1038\/s41375-022-01518-z. Online ahead of print.","author":"Caplan M, Wittorf KJ, Weber KK, Swenson SA, Gilbreath TJ, Willow Hynes-Smith R, Amador C, Hyde RK, Buckley SM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35177813"},{"title01":"A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy","title02":"A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy","journal":"Leukemia","issue":"Leukemia. 2022 Feb 22. doi: 10.1038\/s41375-022-01527-y. Online ahead of print.","author":"Zhang XS, Gale RP, Zhang MJ, Huang XJ, Jiang Q.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35194158"},{"title01":"Venetoclax for arsenic-resistant acute promyelocytic leukaemia","title02":"Venetoclax for arsenic-resistant acute promyelocytic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 17. doi: 10.1111\/bjh.18061. Online ahead of print.","author":"Wang QQ, Wang HF, Zhao JZ, Naranmandura H, Jin J, Zhu HH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35176809"},{"title01":"Cup-shaped nuclei in acute promyelocytic leukaemia","title02":"Cup-shaped nuclei in acute promyelocytic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 20. doi: 10.1111\/bjh.18067. Online ahead of print.","author":"Yu Q, Yu D, Chen X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35187638"},{"title01":"Very late extramedullary relapse of acute myeloid leukaemia as prostatic myeloid sarcoma occurring 24 years post-allograft","title02":"Very late extramedullary relapse of acute myeloid leukaemia as prostatic myeloid sarcoma occurring 24 years post-allograft","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 22. doi: 10.1111\/bjh.18038. Online ahead of print.","author":"Taylor T, Byrne J, Errico G, Clark D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35191543"},{"title01":"The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia","title02":"The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia","journal":"Br J Haematol","issue":"Br J Haematol. 2022 Feb 11. doi: 10.1111\/bjh.18088. Online ahead of print.","author":"Ujjani C, Shadman M, Lynch RC, Tu B, Stevenson PA, Grainger C, Zhu H, Hill JA, Huang ML, Nielsen L, Poh C, Sorensen T, Gopal AK, Warren EH, Till BG, Lee S, Gausman D, Smith SD, Gooley T, Greninger A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35149986"}]